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“The world is full of wonders, but they become more wonderful, not less wonderful when 
Science looks at them.” 
- Sir David Attenborough   
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When bone undergoes trauma or the architecture deteriorates, due to disease and is 
neglected or misdiagnosed, non-unions can occur, whereby bone does not heal correctly. As a 
consequence, patients experience pain, stiffness, loss of mobility and disability. In many cases 
this can result in an inability to perform normal duties in employment, which causes significant 
financial burden to the patient and economy. The repair of these large bone defects remains a 
significant challenge for orthopaedic surgeons.  Bone grafting strategies have been developed 
to repair and restore bone function, however the demand for functional bone grafts is extremely 
high, with an estimated 2.2 million patients worldwide undergoing bone grafting procedures 
annually. Due to an aging population these numbers are expected to double by 2020, which will 
put further burden on health care costs worldwide. Autologous bone grafting remains the 
current standard to repair bone defects and fractures, however, this method of treatment has 
numerous surgical-associated morbidities and complication rates of up to 30%. Therefore, 
researchers are attempting to identify substitute grafting materials which possess the critical 
bone reparative characteristics required for successful healing. To date, a bone graft material 
which is comparable to autologous bone, with fewer associated morbidities is yet to be 
identified, thus, continued research is required to identify and develop new agents to promote 
and accelerate bone repair. 
Agents which have been thoroughly investigated to enhance the bone repair process in 
combination with bone graft substitutes include the use of BMP-2. BMP-2 has proven to be 
successful due to its pro-osteogenic role whereby it promotes osteoblast functionality through 
the regulation of genes necessary for collagen biosynthesis and mineralisation of the 
extracellular matrix (ECM). Osteoblasts are one of the main cell types responsible for bone 
formation and bone repair. These cells are derived from the mesenchymal progenitor cell 
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population, along with endothelial cells and fibroblasts. Work published by our laboratory 
provides evidence that a group of enzymes with peroxidase activity, namely mammalian-
derived myeloperoxidase (MPO) and eosinophil peroxidase (EPO) as well as plant-derived 
soybean peroxidase (SBP) stimulate the migration of fibroblastic cells and promote their ability 
to generate a functional ECM. In addition, we have presented evidence demonstrating the 
ability of these peroxidases, in promoting endothelial cell function and inhibiting 
osteoclastogenesis, suggesting a potential role for these enzymes in bone repair.  
 The work described in this thesis aims to provide evidence that mammalian and plant 
derived peroxidase enzymes including, MPO, EPO and SBP possess pro-osteogenic activities 
by influencing osteoblast functionality. Using physiologically relevant concentrations of 
peroxidases, this study showed that the enzymatic catalytic activities and substrate specificities 
of each of these enzymes which were shown to be different, resulted in differential responses 
in the context of osteoblast function. EPO and SBP demonstrated a well-conserved pro-
osteogenic capacity to stimulate the biosynthesis of collagen I by primary human osteoblasts 
and promote mineralisation of the deposited ECM. In contrast, MPO, while it was able to 
promote ECM deposition, it failed to promote mineralisation and therefore unlikely to 
contribute to bone formation.  
 The ability of EPO and SBP to stimulate mineralisation by osteoblasts suggests that 
these enzymes may possess key properties for promoting bone repair. Of the two tested 
peroxidases however, SBP is more readily available and significantly cheaper than EPO, 
making it an attractive and realistic candidate for further pre-clinical assessment. Data presented 
in this thesis demonstrate for the first time the pro-osteogenic ability of SBP, in combination 
with a commercially available scaffold to significantly accelerate bone repair in an ovine 
critical-sized defect model. This was confirmed by quantitative micro-CT analysis. Histological 
assessment showed evidence of intramembranous bone formation and viable osteoblast and 
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osteocyte cell populations, indicative of bone repair and maturation. These results suggest that 
SBP may be beneficial as a therapeutic agent to accelerate localised repair of damaged bone.    
 The use of rodents over larger animals for different models of bone repair allows for 
high throughput analyses of multiple variables, such as dose and time. Using wildtype mice, 
we established a critical size defect model to validate SBP in this species, prior to investigating 
other models of bone repair. The doses of SBP investigated in this study demonstrated 
significant inhibition of bone formation with increased fibrous tissue present and an absence of 
bone remodelling indicators. The results presented in this thesis highlight the importance of 
further mechanistic investigation, to determine how SBP regulates the remodelling process and 
the necessity for optimisation before assessing the role of SBP in fracture healing. 
 In conclusion, our findings demonstrate for the first time that peroxidase enzymes likely 
regulate multiple cellular processes involved in new bone formation, including collagen I 
biosynthesis, bone matrix mineralisation and osteogenic regulation. Specifically, the plant 
derived peroxidase, SBP, displays significant pro-osteogenic potential by promoting 
intramembranous ossification. The studies presented in this thesis provide the first in vivo 
evidence for peroxidase enzymes as therapeutic agents with the potential to enhance bone repair 
and, identifies peroxidase inhibitors as a preventative target of pathological ossification.   
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BIOLOGY OF BONE 
Bone is a highly specialised connective tissue, consisting of both organic and inorganic 
constituents and is responsible for providing locomotion, supporting and protecting soft tissues, 
maintaining calcium homeostasis and containing bone marrow for haematopoiesis (Datta, Ng, 
Walker, Tuck, & Varanasi, 2008; Robling, Castillo, & Turner, 2006).  The inorganic 
components are responsible for providing compression, strength and stiffness, whereas the 
organic components provide tension properties. The composition of these components varies 
with species, age, sex, the specific bone and the presence of disease (Ontañón, Aparicio, 
Ginebra, & Planell, 2000). From a macroscopic viewpoint, bone appears non-homogenous, 
porous and anisotropic and can be defined between two types of bone tissue. The first type, 
trabecular or cancellous bone has a porosity of 50-95% and can be found in cuboidal and flat 
bones and at the ends of long bones (Figure. 1.1). The highly porous structure is interconnected 
and filled with bone marrow (R. B. Martin, Burr, & Sharkey, 1998). The other type of bone is 
termed cortical or compact bone and is 5-10% porous and contains a variety of different types 
of pores. Vascular pores are formed by Haversian canals that are aligned with the long axis and 
are connected by the transverse Volkmann canals, containing capillaries and nerves. Other 
pores are termed lacunae which are connected through the small canaliculi canals (Cowin, 
1999). This network forms cylindrical structures termed osteons, or Haversian systems (Figure 
1.2). Bone is a very unique tissue by its ability to grow, modify its shape, self-repair and 
continuously renews itself. The growth of bone mostly occurs during childhood, self-repair 
occurs only during fracture healing and its renewal or remodelling remains constant throughout 
our lifetime. The dynamic and highly complex process of bone formation and remodelling 
requires the coordination of osteoblasts and osteoclasts.  These cells are influenced by growth 
factors, cytokines and hormones, which regulate their migration, attachment, proliferation, 












Figure 1.1 Cross-section of a bone showing both cortical and trabecular bone. The cortical 
bone, which forms the cortex of most bones is very dense and contributes to approximately 
80% of the weight of a human skeleton. Cancellous bone is highly vascular and exhibits greater 
surface area than cortical bone which allows for metabolic activity, such as the exchange of 





































Figure 1.2 Microscopical structure of cortical bone. (a) 3D image of cortical bone showing the 
network of blood vessels and nerves interconnected within Haversian and Volkmann canals. 
The canals are a central point for individual osteons or harversian systems. (b) A cut section of 
a Harversian system shows the lamellae containing lacunae cavities, which house osteocytes 

























Osteoblasts, osteoclasts and osteocytes 
Bone contains two distinct cell types, the bone forming osteoblasts and the bone 
resorbing osteoclasts. The functional role between these two cell types are very intimate and 
continues throughout skeletal development and life. Cells from the osteoblastic lineage are 
responsible for the synthesis and secretion of molecules that in turn initiate and regulate 
osteoclast differentiation, which results in a tightly regulated process of bone resorption and 
formation (Teitelbaum, 2000). A third cell type, known as osteocytes plays a key role in this 
regulation of bone formation and remodelling by triggering the differentiation of osteoclasts 
(Matsuo & Irie, 2008). 
  Osteoblasts are cuboidal cells which represent 4-6% of the total bone cell population 
and their main role is the formation of new bone (Capulli, Paone, & Rucci, 2014). These cells 
are derived from mesenchymal stem cells (MSCs) and the commitment towards the 
osteoprogenitor lineage requires the timely expression and synthesis of specific osteogenic 
genes, including bone morphogenetic proteins (BMPs) and members of the Wnt pathway 
(Rawadi et al., 2003). Runt-Related Transcription Factor 2 (RUNX2) is critical in regulating 
osteoblast differentiation and has been shown to upregulate the expression of other key 
osteoblast-related genes, including alpha-1 type I collagen (COL1A1), alkaline phosphatase 
(ALP), bone sialoprotein (BSP) and osteocalcin (OCN) (Fakhry, Hamade, Badran, Buchet, & 
Magne, 2013). Once osteoblast progenitors express RUNX2 they begin the proliferative phase 
whereby the progenitors begin presenting ALP activity and become pre-osteoblasts (Capulli et 
al., 2014). Evidence of the formation of mature osteoblasts is observed by the increase in 
expression of Osterix (OSX) and secretion of bone matrix proteins, OCN, BSP and collagen 
type I.  
 The osteoclast is a multinucleated cell derived from mononuclear cells of the 




macrophage colony-stimulating factor (M-CSF) which is secreted by osteoprogenitors and 
osteoblasts and receptor activator of nuclear factor kappa-B ligand (RANKL), secreted by 
osteoblasts, osteocytes and stromal cells. Combined, these factors regulate transcription factors 
and gene expression in osteoclasts (Karst, Gorny, Galvin, & Oursler, 2004). M-CSF is 
responsible for binding to osteoclast precursors, which leads to their proliferation and inhibits 
apoptosis. Whereas RANKL is critical in promoting osteoclastogenesis, by binding to its 
receptor RANK, in osteoclast precursors and a result induces osteoclast formation 
(Yavropoulou & Yovos, 2008). 
 Whilst the communication between osteoclasts and osteoblasts is critical, the most 
abundant and specialised bone cell type in mammalian bone is the osteocyte. Osteocytes are 
descendants of mesenchymal stem cells through osteoblast differentiation (Bonewald, 2011), 
that become encased within the bone matrix during bone formation. As osteoblasts transition 
to an osteocyte, the expression of various key regulatory markers changes, including reduction 
of ALP and increasing expression of osteocalcin (Mikuni‐ Takagaki, et al., 1995).  The primary 
role of these cells is to maintain mineral homeostasis by detecting micro-fractures and micro-
cracks in bone (Matsuo, Irie, 2008). During remodelling, healthy and dying osteocytes recruit 
osteoclasts at sites of micro-damage. Healthy osteocytes, not directly adjacent to a site of micro-
damage will release anti-apoptotic molecules as a protective mechanism to prevent their own 
apoptosis. Osteocytes at the site of damage however, release pro-apoptotic molecules that 
contains RANKL to recruit osteoclasts directly to the site (Bonewald, 2011). In addition to 
maintaining bone maintenance, osteocytes also act as mechanosensors in the regulation of bone 
mass through hormonal and mechanical signalling. This includes signalling between osteocytes 
and the parathyroid, kidney, cardiac and skeletal muscle to regulate phosphate homeostasis and 




The maintenance and function of the skeletal system relies on a variety of cell types and 
factors, but predominantly the communication between osteoclasts and osteoblasts (T. J. Martin 
& Sims, 2005). However, whilst much of the maintenance is the responsibility of these two cell 
types, they rely on the specialised regulation and mechanosensory of osteocytes. Thus, a 
functional, highly communicative bone network, extending from the pre-osteoblast to the 
mature osteocyte and bone resorbing osteoclast is important for maintaining the integrity of 
bone as a tissue. 
 
Bone remodelling 
Bone is a dynamic organ that constantly undergoes remodelling, where old bone is 
continuously replaced by new bone. This cycle consists of three key phases, initiation of bone 
resorption, which is orchestrated by osteoclasts, transition from resorption to bone formation 
and then a long period of bone matrix formation mediated by osteoblasts, which then becomes 
mineralised (Sims & Gooi, 2008) (Figure 1.3). The initiation phase involves the recruitment 
and differentiation of osteoclast precursors to mature osteoclasts, which maintain bone 
resorption. This occurs by the expression of RANKL of bone lining cells which stimulates 
RANK on osteoclast precursors. In addition, nearby osteoblasts produce the decoy receptor 
osteoprotegerin (OPG), which effectively inhibits osteoclast formation and helps in regulating 
the extent of bone resorption (Bucay et al., 1998). As the bone matrix becomes resorbed, 
numerous factors are released which were embedded during the previous cycle of bone 
formation. This initiates the transition phase whereby the osteoclasts stimulate differentiation 
of osteoblast precursors through the release of various factors. These regulatory factors of bone 
formation include, insulin-like growth factors (IGF), fibroblast growth factors (FGF), 
transforming growth factor β (TGF-β) 1 and 2, BMPs and platelet-derived growth factors 




amount of bone resorbed by the osteoclasts determines the concentration of factors released, 
thus ensuring bone formation remains proportional to the level of resorption. Once bone 
resorption has been completed the osteoclasts undergo apoptosis from released calcium and 
mononuclear phagocytes of haematopoietic origin or osteoblast-lineage cells complete the 
resorption process by forming a “reversal line” (Van Tran, Vignery, & Baron, 1982). The final 
termination phase, which is comprised of osteoblastic bone formation occurs at a much slower 
rate, taking approximately 3 months, compared to 3 weeks of bone resorption. The osteoblasts 
form new bone by communicating with one another via gap junctions as well as by releasing 
factors. Once bone formation is nearing completion and the secretion of osteoid begins to slow, 
osteoblasts begin differentiation into either bone lining cells, which remain on the surface or 
into osteocytes and become embedded into the bone matrix (Eriksen, 2010). Once bone 
formation has ceased and bone lining cells cover the bone surface, the matrix becomes 
mineralised through the signalling of osteocytes within the matrix. When the matrix is 
completely mineralised, it reaches a stable state until signalling cues the next cycle of 
remodelling. Through these intracellular communications bone can respond to various stimuli 
including, hormonal, mechanical and inflammatory changes. However, certain conditions can 
alter or impede the remodelling process which includes bone fractures, large osseous defects, 
and even systemic diseases such as osteoporosis. These forms of bone damage require bone 















Figure 1.3 Three-phase model of bone remodelling. Osteoclast (grey) and osteoblast (blue) 
lineage cells are shown on the bone surface (orange). Osteocytes (star-shaped) and the 
canaliculi (blue lines) are shown embedded in the bone. The initiation phase begins with the 
recruitment of haematopoietic precursors. Osteoblast linage cells express osteoclastogenic 
ligands such as RANKL to induce osteoclast differentiation. Once differentiated, the osteoclasts 
become multinucleated and begin to resorb old bone. The second phase, transition, represents 
the switch from bone resorption to formation, via coupling and diffusible factors and membrane 
bound molecules (green). The final termination phase involves the complete formation of 
resorbed bone by the osteoblasts. The mature osteoblasts eventually flatten and become bone 





























 Bone is comprised of both inorganic mineral and organic matrix. Freshly synthesised 
osteoid prior to being mineralised, contains about 94% collagenous proteins, which are 
predominantly type I collagen. Other non-collagenous proteins of the organic matrix include 
osteocalcin, osteonectin, osteopontin, fibronectin, BSP, BMPs and other growth factors 
(Mizuno, Fujisawa, & Kuboki, 2000; Young, Kerr, Ibaraki, Heegaard, & Robey, 1992). These 
proteins are found embedded within the bone matrix and play crucial roles in signalling bone 
remodelling or influencing the mineralisation process (Delany et al., 2000; Ducy et al., 1996). 
As the organic matrix begins to be mineralised, the quantity of present mineral increases to 70% 
of its total content within 2 weeks. The final 30% of mineral is then slowly deposited over the 
next few months (Gunzburg & Szpalski, 2004). The inorganic component of bone consists 
mostly of phosphate and calcium, however other minerals are also abundant including, 
bicarbonate, sodium, potassium, citrate, magnesium and zinc (Downey & Siegel, 2006; Pereira, 
Rodrigues, Rodrigues, Oliveira, & Gama, 2017). The two key minerals calcium and phosphate 
form the major constituent of inorganic bone, called hydroxyapatite, which is represented by 
the chemical formula Ca10(PO4)6(OH)2. The collagenous and non-collagenous proteins 
combine to form a scaffold for the deposited hydroxyapatite crystals and this final association 
between the organic and inorganic components leads to the stiffness and strength of bone tissue 
(Datta et al., 2008). The calcified bone matrix provides both mechanical support and is essential 
in maintaining bone homeostasis. However, factors such as age, nutrition and disease can lead 
to varied concentrations of bone matrix proteins which can consequently contribute to increased 






BONE DAMAGE   
The highly adaptable nature of bone allows for efficient remodelling which prevents the 
occurrence of fractures. However, fracturing and bone damage can still arise, either by sudden 
loading which surpasses the bones strength, or by continuous activity of a lower loading which 
accumulates bone damage overtime. Once a bone fractures, the complex signalling between 
cells and stimuli leads to an automatic healing process to repair the bone. The healing process 
requires the coordination of several tissues which are directly influenced by the mechanical 
environment. However, in some cases, the mechanical and biological factors prevent the 
damaged bone from reforming properly and this results in either delayed union or non-union.      
 
Mechanisms of bone repair 
 Trauma or deteriorating bone architecture, because of age or disease can reduce the 
bones structural integrity when combined with bone loading, leading to the creation of bone 
fractures. There are two distinct processes by which fractured bone can be repaired which are 
termed primary and secondary bone healing. Primary healing which includes contact healing, 
gap healing and direct union is characterised by union of the fractured bone. This form of 
healing can only occur in a mechanically stable environment, which can be supplied by using 
implants such as plates and screws (Einhorn, 1998). The haematoma that forms within the 
fracture gap initially after injury is removed by the contact between the fracture ends. Once 
removed, osteoclasts undergo a tunnelling resorptive response whereby they move from one 
side of the fracture to the other and form new harversian canals, by providing a pathway for 
penetrating blood vessels (McKibbin, 1978) (Figure 1.4A). Osteoblasts immediately follow the 
osteoclasts and form new osteons which bridge the fracture gap and the new bone begins to 
gain strength through calcification and remodelling, with the additional application of static and 




 Secondary or indirect fracture healing is the most common form of healing and is 
comprised of both intramembranous and endochondral bone repair. Intramembranous 
ossification is characterised by direct differentiation of MSCs into osteoblasts and occurs 
internally of the periosteum at the proximal and distal edges of the callus and forms a hard 
callus (Figure 1.4B). The bridging of the hard callus across the fracture gap provides the bone 
with the initial stabilisation and biomechanical function (Dimitriou, Tsiridis, & Giannoudis, 
2005; Thompson, Miclau, Hu, & Helms, 2002). Endochondral ossification on the other hand, 
occurs externally to the periosteum, adjacent to the fracture site where the bone is much less 
stable. In addition, MSCs in endochondral bone differentiate into chondrocytes and deposit a 
cartilaginous matrix, which overtime is degraded and replaced by bone. Fracture repair requires 
several processes in order to successfully reinstate mechanical function and stability to the bone. 
This includes an acute inflammatory response, recruitment of MSCs, generation of a 
cartilaginous callus, revascularisation, mineralisation of the callus and final bone remodelling. 
Immediately following fracturing, a haematoma forms and consists of peripheral and 
intramedullary blood and bone marrow cells. The injury also initiates an inflammatory response 
and whilst it is known that chronic inflammation is detrimental to bone, the brief and highly 
regulated secretion of pro-inflammatories in the form of an acute response, is essential to the 
repair process. This acute response peaks within the first 24 hours of injury and is completed 
by 7 days post injury. Several pro-inflammatory factors are released at this time and include, 
chemokines, tumour necrosis factor-α (TNF-α) and interleukin-1 (IL-1), IL-6, IL-8, IL-11 and 
IL-18 (Gerstenfeld, Cullinane, Barnes, Graves, & Einhorn, 2003; Koch et al., 2001; Y.-C. Liu 
et al., 2014; Volpin et al., 2014). These factors are essential for the recruitment of inflammatory 
cells, differentiation of osteoblasts and osteoclasts and promote angiogenesis (Sfeir, Ho, Doll, 
Azari, & Hollinger, 2005; Yang et al., 2007). For the formation of new bone to repair the 




systemic circulation, followed by differentiation into osteogenic cells. The ability for MSCs to 
be recruited to sites of bone damage is regulated by stromal cell-derived factor-1 (SDF-1, 
CXCL12) and its receptor CXCR4, expressed on MSCs (Kitaori et al., 2009). Once MSCs are 
recruited, a molecular cascade leads to collagen type I and II matrix production and the 
upregulation of several signalling factors. The generation of an initial cartilaginous callus which 
later becomes mineralised, resorbed and replaced with bone is critical in the healing process. 
This endochondral formation occurs in between the fracture ends and forms a less stable soft 
tissue callus. During this process TGF-β and GDF-5, a close member of the BMP family 
promote chondrogenesis and endochondral ossification (T. J. Cho, Gerstenfeld, & Einhorn, 
2002). At the same time, BMP-2, -5 and -6 induce cell proliferation and initiate 
intramembranous ossification at the periosteal sites. This generates a hard callus and once it has 
bridged the fracture gap it provides the site with a semi-stable structure for weight bearing 
(Marsell & Einhorn, 2009). Another critical component for successful fracture healing is the 
revascularisation of the fracture gap. This process firstly requires chondrocyte apoptosis and 
degradation of the cartilaginous matrix, to allow the ingrowth of blood vessels at the fracture 
site (Ai-Aql, Alagl, Graves, Gerstenfeld, & Einhorn, 2008). Vascular endothelial growth factor 
(VEGF), expressed in high levels by osteoblasts and chondrocytes, is critical in the regulation 
of vascular regeneration within the fracture gap, by promoting blood vessel invasion and 
transforming the cartilaginous matrix into a well-vascularised osseous tissue. Here, VEGF 
promotes both the proliferation of endothelial MSCs into a vascular network and angiogenesis 
(Keramaris, Calori, Nikolaou, Schemitsch, & Giannoudis, 2008). Once vascularisation has been 
established the cartilaginous callus is resorbed and replaced with a bony callus. This is brought 
about primarily by M-CSF, RANKL and OPG, which initiate resorption of the mineralised 
cartilage and recruit osteoblasts and osteoclasts to begin forming new bone (Kon et al., 2001). 




bone formation (Chen & Alman, 2009). Other molecules such as matrix metalloproteinases 
(MMPs) are also involved in endochondral ossification. This family of proteases is responsible 
for extracellular matrix (ECM) degradation and subsequent bone remodelling (Ortega, 
Behonick, & Werb, 2004). BSP is also observed near the resorptive front between the vascular 
bone and remaining cartilage where it acts as the nucleator for hydroxyapatite crystals 
(Scammell & Roach, 1996). As the hard callus forms, the calcified cartilage is replaced with 
woven bone and the callus within the fracture gap becomes increasingly stabilised. The final 
process to complete fracture healing is remodelling of the hard callus to normal bone. This 
involves the activation of a second resorptive phase whereby woven bone is resorbed and 
replaced with mature lamellar bone, which is orchestrated by IL-1, TNF-α and BMP-2 (Ai-Aql 
et al., 2008; Marsell & Einhorn, 2009). The process can take 3-4 weeks in humans, however, 
the completion of remodelling and a fully restored bone structure can take several years (Hall, 
1963). In cases where mechanical stability is not created from bone remodelling or there is an 
inadequate blood supply, the development of fibrous non-union is likely to occur. This is also 
the case for larger fractures where bridging of the fracture ends is not successful.  
 Interestingly, the repair mechanisms of bone damage are not consistent between all 
bones of the skeleton. In long bones and limbs which are fractured and damaged, bone healing 
occurs via intramembranous and endochondral ossification. However, in flat bones such as 
calvarial and facial bones, the repair process occurs by intramembranous ossification alone, 
with no chondrogenic cells present (Alberius & Johnell, 1991). Furthermore, comparisons of 
bone formation between long and flat bones have revealed that the rate of healing in long bones 
occurs much more rapidly than flat bones. This is likely due to the absence of mechanical 
loading of the flat bones, which is a key physiological factor for regulating bone formation 
(Lim, Lee, Yun, Shin, & Park, 2013). These differences in healing rate between bones must be 




fast resorbing scaffolds would only be suitable in long bones to match the rate of new bone 

























Figure 1.4 Primary and secondary fracture healing. Healing of a fracture is dependent on the 
stability of the fracture site. When bone is undergoing primary fracture healing, osteoclasts 
osteoclasts from the intact bone move across the fracture gap via tunnelling, resorptive 
mechanisms, to re-establish Harversian Canals. Along with the formation of new blood vessels, 
osteoblasts follow the tunnelling osteoclasts and produce new bone and fill the canals with 
osteons (A). Secondary fracture healing undergoes a series of phases in order to restore 
mechanical stability in addition to repairing the fracture. The three phases of fracture healing 
begin with the initial haematoma (B1). Bleeding from the bone and surrounding soft tissue 
results in a haematoma, providing some stability. The clotted site provides a framework for an 
inflammatory response (B2), leading to an influx of numerous cell types and release of various 
cytokines. Granulation tissue also begins to replace the haematoma and a cartilaginous callus 
begins to form. During the repair phase (B3), the external cartilaginous callus is converted into 

















Limitations of bone regeneration and repair 
 Despite the characteristic regenerative capabilities that bone possesses, there are an 
array of conditions which negatively affect and impede the repair process. One of the main 
limiting factors of bone regeneration is the extent of damage, which beyond a certain degree or 
size will not naturally regenerate. Even in the case of smaller fractures, numerous factors can 
compromise the repair process, which include the patient’s systemic status, nature of the injury, 
local host response and pharmacologic factors.  
When considering a patient’s systemic status there is an increased occurrence of 
fractures in women compared to men after the third decade of life (Hedlund & Lindgren, 1987). 
However, there is no specific data pertaining to gender and delayed healing. Whilst gender does 
not directly affect healing, aging and its associated health conditions can impact the repair 
process. Hormone deficiency, for example oestrogen, as a result of menopause in women is one 
of the most important factors in the pathogenesis of osteoporosis and as a consequence, 
significantly affects early fracture healing (Richelson, Wahner, Melton III, & Riggs, 1984). The 
link between hormone deficiency and delayed union have been further supported by 
replacement therapy studies, which have demonstrated that maintaining normal hormone levels 
is critical in ensuring bone healing (Felson et al., 1993).   
Location of bone damage is another critical determinant of successful healing. It has 
been well reported that bone fractures can cause disruption of the bloody supply and 
consequently the bone marrow (Carano & Filvaroff, 2003). If the vascularisation is 
compromised, which supplies the osteogenic cells, then it is expected that disruption would 
impede the repair process (Gittens & Uludag, 2001). Another contributor to delayed or non-
union is deep infection at the wound site. An infected non-union is defined as a persistent 
infection at the fracture site for a duration of 6-8 months (Meyer, Weiland, & Willenegger, 




stable fixation which leads to mechanical instability (Friedrich & Klaue, 1977). Furthermore, 
the generation of a chronic inflammatory reaction in response to infection can also have 
deleterious effects on bone regeneration (Thomas & Puleo, 2011). 
Within the host, the availability of collagen significantly influences callus formation 
and overall fracture healing. In a mechanically stable fracture, collagen type I is the major 
collagen type present, with collagens type II and V present within the trabeculae (Page, Hogg, 
& Ashhurst, 1986). Collagen type III is another crucial protein found at fracture sites and is 
expressed in early osteoblast differentiation. As the osteoblast matures and remodelling 
progresses, the level of collagen type III rapidly declines. However, in the case of a non-union 
it has been shown that type III collagen levels remain elevated and there is an apparent 
elongation of the osteoblasts early phase, resulting in fibrous tissue formation and consequently 
impaired bone repair (Lawton, Andrew, Marsh, Hoyland, & Freemont, 1997).  
Finally, pharmacologic factors administered prior to fracturing or damaging bone can 
significantly impair the healing process. This includes systemic corticosteroid use which has 
been shown to inhibit bone repair, by reducing the synthesis of collagen type I and growth 
factors, as well as decreasing osteoblast activity (Waters et al., 2000). In addition, whilst chronic 
inflammatory responses can be detrimental to the repair process, the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) has been shown to have inhibitory effects on fracture healing by 
impeding blood flow to the fracture gap (Murnaghan, Li, & Marsh, 2006). It has also been 
shown that patients who smoke were 37% more likely to develop non-union and twice as likely 
to develop infection, which can have further detrimental effects on repair (Gaston & Simpson, 
2007). With many reported factors that can influence non-union, the requirement to intervene 
to correctly repair the defect is essential. This can be done through orthopaedic surgery, by 





Types of non-union 
 A bone fracture is termed a non-union when the fracture ends fail to unite and requires 
additional treatment before successful healing can occur. Traditionally, non-unions are 
classified according to their radiographic appearance, as either hypervascular or avascular 
(Scott P Bruder, Fink, & Caplan, 1994). Hypervascular non-unions are associated with a 
sufficient blood supply with decreasing callus formation and appear as an elephant-foot or 
horse-shoe configuration (Panagiotis, 2005) (Figure 1.5). Additionally, oligotrophic non-unions 
have an adequate blood supply but minimal callus formation. The adequate blood supply 
present in these forms of non-union suggests the presence of a biological response and therefore 
the absence of fracture healing is due to insufficient mechanical stability. Alternatively, 
avascular non-unions have little or no callus formation due to an insufficient blood supply or 
bone forming cells (Phieffer & Goulet, 2006). These situations arise following bone loss or 
removal of the periosteum. Types of avascular non-unions include, severely displaced or 
comminuted fractures, defect non-unions, atrophic non-unions, that are comprised of thin 
fracture ends with excessive scar tissue and torsion wedge non-unions, that arise when the bone 
fragment has only healed at one end (Ebnezar & John, 2016; Panagiotis, 2005) (Figure 1.6). 
Avascular non-unions can arise not only from high-impact injuries but also following multiple 
failed procedures leading to significant bone loss (Alt et al., 2006). The treatment of non-unions 
involves the use of therapeutic interventions that improve the mechanical and/or biological 
environment at the fracture site. In cases where there is sufficient callus formation, such as 
hypervascular non-unions, the main cause of failure to heal is due to poor fracture stability. 
Once mechanical stability is achieved, calcification of the fibrous cartilage occurs, by the 
penetration of new blood vessels, allowing for bone remodelling and eventually bone union 
(Schenk, Müller, & Willenegger, 1968). Unlike hypervascular non-unions, avascular non-




filled with bone graft materials and supported by stable fixation. Currently, there are numerous 
methods of fixation to stabilise non-unions and a variety of bone graft materials that provide 
scaffolding, promote cellular differentiation and contain growth and differentiation factors 























Figure 1.5 Types of hypervascular non-unions. Highly vascularised non-unions are defined by 
their radiographical appearance. The presence of a callus defines them as either, elephant-foot 
non-unions (A) or horse-shoe non-unions (B). Hypervascular non-unions with no observable 









































Figure 1.6 Types of avascular non-unions. Avascular non-unions are defined as bone fractures 
with little blood supply and are defined based on their appearance and size. Comminuted non-
unions (A); Defect non-union (B); Atrophic non-union (C); Torsion wedge non-union (D) 




































The repair of large bony defects and non-unions that arise as a result of bone disease, trauma or 
tumour removal remains a significant challenge to orthopaedic surgeons. If bone damage is 
neglected, development of non-unions can occur, whereby the bone cannot repair itself 
correctly, which often leads to pain, stiffness of nearby joints and loss of mobility. Along with 
the associated morbidities, this disability often results in the patient being unable to resume 
normal duties in employment, which causes significant financial burden to the patient and the 
economy (Babhulkar, Pande, & Babhulkar, 2005; Bondurant, Cotler, Buckle, Miller-crotchett, 
& Browner, 1988; Kanakaris & Giannoudis, 2007). Therefore, in order to restore and stabilise 
the bone, bone grafting or the use of bone graft substitutes is required. To further complicate 
matters, the demand for functional bone grafts is becoming extremely high, with an estimated 
2.2 million patients undergoing treatment for bone defects annually worldwide. This generates 
huge economic cost to health care and these numbers are expected to double by 2020, due to 
population ageing (B. Baroli, 2009; Giannoudis, Dinopoulos, & Tsiridis, 2005).  
 
Fracture stabilisation 
 To repair large bone defects which are likely to undergo delayed or non-union, the 
mechanical and biological problems must both be addressed. Stabilisation of the bone is 
essential in ensuring the additional biological component can promote successful bone repair. 
Two forms of fixation are currently available, internal and external fixation (Figure 1.7). Plate 
fixation and intramedullary nailing are the most popular treatment options of internal fixation, 
by their ability to provide adequate stability without causing excessive rigidity (Rodriguez-
Merchan & Forriol, 2004). Plate fixation can be used with or without bone grafts and is often 
accompanied by compression, which encourages ossification of the non-union. The 




vasculature. Furthermore, the risk of infection is slightly higher compared to simple bone 
grafting techniques of uninfected tibia non-unions (Smith, 1974). Intramedullary nailing is the 
most common form of internal fixation and is the preferred treatment for most diaphyseal non-
unions. Unlike plate fixation, reamed intramedullary nailing provides the advantage of reaching 
full function earlier, including weight-bearing and motion of adjacent joints. This is due to the 
effect of reaming, which increases the contact area between the nail and the rough surface of 
the medullary cavity. In addition, reamed intramedullary nailing possesses a broad range of 
applications, primarily for the treatment of uninfected non-unions. However, treating an 
infected, or previously infected non-union by nailing, has been associated with increased risk 
of infection (Phieffer & Goulet, 2006). Despite the association with infection, there have been 
reports of 100% successful union using reamed intramedullary nailing for treating tibia non-
unions (Megas, Panagiotopoulos, Skriviliotakis, & Lambiris, 2001). In cases of non-unions 
with bony defects, it is recommended that the reamed nailing is supplemented with bone graft 
materials (Finkemeier & Chapman, 2002). For patients who present with delayed union and a 
previous infection, external fixation is the preferred method of stabilisation. External fixators 
present as either unilateral or circular fixation systems that provide several advantages 
including, wound access, distant stabilisation of the bone fragments and motion of adjacent 
joints which encourages patient mobility. Furthermore, external fixators cause less disruption 
to soft tissues and blood supply, which makes them beneficial for patients who present with 
open wounds or skin contusions (Fragomen & Rozbruch, 2007). Often, external fixation can 
successfully unite bone fractures, however in some patients the fixation can be ineffective and 
must be replaced. If the reoperation involves opening and exposing the non-union, it is 
recommended that bone grafting be done at the same time. Alternatively, if new fixation is 




(Rodriguez-Merchan & Forriol, 2004). In most cases, reoperation of an internal or external 





























Figure 1.7 Popular techniques of fixation for fractures. Commonly used internal fixation 
strategies include, plate fixation (A) and intramedullary nailing (B). In place of internal fixation, 
an external fixator (C) can provide greater stabilisation, which is often required in more 





























Osteogenic, osteoinductive and osteoconductive properties 
 Once mechanical stability has been achieved, the biological issues associated with large 
bone defects can be addressed, through the use of bone grafts. Three major characteristics of 
bone graft and graft substitutes that are essential to bonding, or osteointegration of the graft 
material to the host bone are osteogenesis, osteoinduction and osteoconduction. To successfully 
qualify as a bone graft, the material must possess at least one of these functions. Grafting 
materials harvested from donors may contain living osteoprogenitor cells which can survive 
transplantation and have the potential to differentiate into osteoblasts and osteocytes. The 
ability for grafting materials to contain these viable cells characterises the material as 
osteogenic (Cypher & Grossman, 1996). Bone graft and graft substitutes which stimulate 
proliferation of stem cells and the differentiation of stem cells to osteogenic cells are termed 
osteoinductive (Perry, 1999). Several growth factors are responsible for influencing this process 
and include BMPs, PDGFs, FGFs and other members of the TGF-β superfamily (Cypher & 
Grossman, 1996). Finally, the term osteoconductive refers to the graft material’s ability to 
provide an interconnected structure which allows new cell migration and blood vessel 
formation, whilst also providing a framework for new cell attachment of osteoblasts and 
osteoprogenitors (Hak, 2007).   
 
Autogenous and allogenic bone graft 
 Autogenous bone grafts which is bone tissue harvested from the patient is considered 
the current gold standard for reconstruction of large bone defects, as it possesses osteogenic, 
osteoinductive and osteoconductive properties. It also provides minimal immunogenic rejection 
and ample histocompatibility (Bauer & Muschler, 2000a; Homma, Zimmermann, & Hernigou, 
2013; Perry, 1999; Samartzis, Shen, Goldberg, & An, 2005). The bone is often harvested from 




before being implanted into the damaged site (Dimitriou, Mataliotakis, Angoules, Kanakaris, 
& Giannoudis, 2011). Although autologous bone is the best replacement material for a defect 
or fracture site, this method has a complication rate of up to 30%. Complications include, donor-
site morbidity and pain from harvesting, extended hospitalisation and also surgical-associated 
morbidities such as, infection, inflammation and chronic pain (Ami R. Amini, Cato T. 
Laurencin, & Syam P. Nukavarapu, 2012; Banwart, Asher, & Hassanein, 1995). The quantity 
of bone that can be harvested is also very limited, which can pose a problem for larger defects 
(Jimi et al., 2012).  
 A common alternative to autogenous grafting is the use of allogenic bone, which 
accounts for approximately one-third of bone grafting procedures (T. Boyce, J. Edwards, & N. 
Scarborough, 1999). The use of allografts which are taken from donors or cadavers eliminates 
several patient morbidities and issues associated with limited supply.  However, allografting 
also presents a number of hazards, including risk of disease transmission from the donor. The 
risk of HIV transmission is estimated to be 1 in 1.6 million and other viruses including hepatitis 
B and C have also been previously reported to be transmitted through allograft material (T. 
Boyce et al., 1999).  Thorough screenings of donors and better sterilisation techniques such as 
tissue freezing and sterilisation by radiation have aided in minimising disease risk (Vangsness 
et al., 2003). However, these processing techniques eliminate any osteogenic capabilities and 
negatively affect the osteoinductive and osteoconductive potential of the graft material (Lane 
& Sandhu, 1987), which significantly decreases their biological capacity (Anderson et al., 1999; 
Oklund, Prolo, Gutierrez, & King, 1986).  
Due to the above-mentioned limitations of natural bone grafts, a wide variety of 
synthetic bone graft substitutes have been developed. A summary of various bone graft and 
bone graft substitutes and their respective properties are described in Table 1. Many of these 




polymers, ceramics and composites. Additionally, factor and cell-based strategies have been 
investigated, which can be used alone or in combination with other materials (Laurencin, Khan, 
& El-Amin, 2006). The development of a successful graft however, must possess the 


























Table 1.1 Properties of bone graft and bone graft substitutes 
Class Description Properties of action 
Autograft Used alone  Osteogenic 
 Osteoinductive 
 Osteoconductive 
Allograft Used alone or in combination with other materials  Osteoinductive 
 Osteoconductive 
Ceramic based Includes calcium phosphate, hydroxyapatite, used alone or in 
combination with other materials. e.g., Mastergraft
®
 
 Osteoconductive  
Collagen based Biodegradable scaffold used alone or in combination with other 
materials. e.g., BioMend, CollaCote 
 Osteoconductive 
Factor based Natural and recombinant growth factors used alone or in 











Ceramic and collagen bone graft substitutes 
Approximately 60% of bone graft substitutes currently available contain ceramics. 
Common commercially available forms include porous implants, non-porous implants and 
granular particles with pores, which all possess excellent osteoconductivity. The interest in 
using ceramics, specifically those comprised of calcium phosphates (CaP) is mostly because 
the primary inorganic component found in bone is calcium hydroxyapatite (HA), a subset of 
calcium phosphate (Zwingenberger et al., 2012). Whilst HA is naturally occurring in bone and 
has osteoconductive and osteointegrative properties, the high Ca/P ratio (1.67) and crystallinity 
causes a slow resorption rate (W. Wang & K. W. K. Yeung, 2017). As an alternative to HA, 
beta-tricalcium phosphate (β-TCP) use has been explored as it possesses a lower Ca/P ratio 
(1.5) which enables accelerated degradation and resorption (Torres, Tamimi, Alkhraisat, 
Prados-Frutos, & Lopez-Cabarcos, 2011).  However, this results in significantly weaker 
mechanical properties (LeGeros, 2002). To address this issue, HA and β-TCP are combined to 
form biphasic calcium phosphate (BCP), where the resorption rate and mechanical properties 
can be controlled. A BCP ratio which has been rigorously tested and deemed suitable 
commercially is 15% HA:85% β-TCP, which is provided by several companies, including the 
Mastergraft® products provided by Medtronic (Khan & Lane, 2004).   
Collagen type I is the main organic component of bone, accounting for 97% of protein 
found in bone (Glimcher & Lian, 1989). Collagen which serves as a template for biological 
bone, is one of the most commonly used scaffold materials, with a variety commercially 
available e.g., CollaCote™ and BioMend®. Type I collagen scaffolds are known to have good 
biocompatibility, biodegradability, osteoconductivity and weak antigenicity (W. Wang & K. 
W. K. Yeung, 2017). Furthermore, collagen scaffolds have been studied exhaustively and have 
been shown to support sustained release of a variety of osteoinductive factors, which makes 




1999). One drawback of collagen-based materials are the mechanical properties, which are very 
weak and so, these materials are often found in the form of composites such as collagen-HA 
(Kikuchi et al., 2004). Therefore, consideration of the bone type and mechanical properties are 
needed for graft substitutes. High weight-bearing bones, such as the femur, when fractured or 
presenting with a non-union require greater stiffness and structural stability. Whereas low 
weight-bearing applications such as the repair of cranial damage can benefit from materials that 
provide accurate aesthetic remodelling with reduced weight-bearing support.  Although 
collagen and ceramic graft materials demonstrate high biocompatibility and osteoconductivity, 
new bone formation is often limited due to their poor osteoinductive capabilities (Yuan et al., 
2002), therefore the addition of growth factors or cells is often required. 
 
Bone morphogenetic proteins 
 Growth factors and proteins which reside in bone are responsible for the regulation of 
numerous cellular functions, including the production and resorption of bone. BMPs which are 
members of the TGF-β superfamily, are biologically active molecules with the ability to 
promote recruitment, proliferation, differentiation and migration of bone-forming cells (Lind, 
Eriksen, & Bünger, 1996). The capacity for BMPs, specifically BMP-2, 4 and 7 to bind to 
receptors on MSCs, osteoblasts and chondrocytes and promote their activity makes them 
potential osteoinductive agents for clinical use (Kloen et al., 2003). BMPs are often delivered 
to a surgical site by a variety of graft materials including allogenic bone and synthetic scaffolds. 
The osteogenic and osteoinductive potential of BMPs has been thoroughly proven in both 
preclinical and clinical studies with an analogous performance to autogenous bone (Boden, 
2001; Friedlaender et al., 2001; Mussano, Ciccone, Ceccarelli, Baldi, & Bassi, 2007). Despite 
the potential of BMPs, only recombinant human BMP-2 and 7 have been approved for select 




craniomaxillofacial surgeries and as a replacement for autogenous bone in tibial non-unions 
(Boden & Schimandle, 1995; Ristiniemi et al., 2007; Vaccaro et al., 2005). Although reports 
suggest multiple benefits for the use of BMPs in orthopaedic surgery, there are numerous 
complications to consider. In spinal surgery alone there have been reported complications of 
neurological impairment, bone resorption at the graft site and neck swelling (Benglis, Wang, & 
Levi, 2008; Wong, Kumar, Jatana, Ghiselli, & Wong, 2008). These reports, along with the 
significant high cost of using BMPs (Garrison et al., 2007) suggests the requirement to identify 
other factors possessing osteoinductive properties, that result in fewer adverse side effects and 
















In order to biomechanically simulate humans as accurately as possible and assess the effects of 
experimental bone graft substitutes of defect and fracture repair, numerous animal models have 
been established. With the availability of numerous animal species and experimental 
approaches to test the capacity of graft materials, several factors need to be taken into 
consideration when determining the appropriate model for the tested material. Species of 
animal, age of the animal, type of defect, stability of the defect and anatomic location all have 
an influence on the quality and type of bone that forms within the defect site (Bosch, Melsen, 
& Vargervik, 1998). Therefore, researchers must ensure that the biological, biochemical and 
physiological characteristics of an animal species and the selected defect model will accurately 
replicate the repair mechanisms anticipated in humans. 
 
Non-union models of bone repair  
 A critical prerequisite for any model used to test bone graft substitutes is to ensure that 
the empty defect heals more slowly than the experimental defect. The ideal scenario for any 
model is one by which the defect undergoes osseous union only with the addition of an applied 
bone graft substitute. A wound of this size is termed a critical size defect and was defined by 
Schmitz and Hollinger as the smallest intraosseous wound that would not heal by bone 
formation during the lifetime of the animal (Schmitz & Hollinger, 1986). As a result, the defect 
heals by fibrous connective tissue formation, not by new bone regeneration. It is hypothesised 
that this is due to the inability for cells to differentiate into osteoblasts and chondroblasts in the 
central region of the defect due to a lack of tissue factors (e.g., BMPs) to induce a rate of cellular 
differentiation. The reduced presence of these cells results in a failure to mineralise the matrix 
within the central region of the defect, leaving behind a dense fibrous connective tissue 




utilising this model, a number of other factors must also be considered which can influence 
healing of the defect, including animal species, animal age, anatomic location of the defect, 
bone structure and vascularisation and mechanical loading (Reichert et al., 2009; Schmitz & 
Hollinger, 1986).  
 
Animal species as a testing model 
 Several animal species have been used to simulate the human in-vivo environment, 
physical conditions and comparability of bone graft substitutes, including rodents, rabbits, dogs, 
sheep, goats and pigs. When selecting a specific animal as the test model, certain factors must 
first be considered. Firstly, the animal model must clearly demonstrate comparable 
physiological and pathophysiological similarities to humans. Further selection criteria that must 
also be considered is cost of animal procurement, availability, tolerance to captivity and ease 
of housing (Pearce, Richards, Milz, Schneider, & Pearce, 2007). Additionally, it is important 
to consider the number of implants per animal, duration of the experiment and expected 
differences in biological response, before determining the most suitable animal species 
(Upman, 2006). Whilst there are numerous animal models available to test bone graft materials, 
as mentioned above, this thesis will focus primarily on rodents and sheep. 
 Rodents are a commonly used animal for bone-related research as they are small, easy 
to handle and relatively inexpensive to obtain and house, which is important to consider due to 
the long housing times required in orthopaedic research. For these reasons they are often 
considered the first in-vivo model for assessing the effectiveness of experimental bone graft 
substitutes (Gomes & Fernandes, 2011). Implantation of graft substitutes such as ceramics, 
collagen, BMPs and stem cells in various rat bone defect models have all successfully 




Dhar, Chun, Gharibjanian, & Evans, 2007). This included the use of critically sized femoral 
and calvarial defects. It is also a common animal subject to study multiple aspects of bone 
regeneration, including fracture, defect repair, joint infection and osteoporosis (An & Freidman, 
1998). Although mice are a much smaller rodent than rats, they have become increasingly 
popular as an animal model for skeletal research, specifically to screen potential novel 
substances for osteogenesis and chondrogenesis (An & Freidman, 1998). A highly useful model 
used in mice is the critical-size calvarial defect model, with a defect size > 2 mm considered a 
critical non-healing defect (Aalami et al., 2004; Cowan et al., 2004; Im et al., 2013; Levi et al., 
2010). Whilst both rats and mice possess numerous advantages as pre-clinical animal models 
for investigating and assessing the potential of novel bone graft substitutes, there are limitations 
to consider. In particular, compared to larger animals such as sheep, rodents have much smaller 
long bones which can be difficult to use in fixation models and do not form haversian-type bone 
tissue, unlike larger animals and humans (Li et al., 2015; M Martiniaková, Grosskopf, 
Vondráková, Omelka, & Fabiš, 2005).  
 The use of small animals provides researchers with a significant amount of knowledge 
with regards to the effectiveness of tested bone graft substitutes. However, large animal models, 
such as sheep have been developed to verify the potential of novel materials, closer to a clinical 
setting. The advantages of using mature sheep is firstly, they possess a body weight similar to 
adult humans and the comparable dimensions of their long bones to humans allows for the use 
of human implants (Newman, Turner, & Wark, 1995). Secondly, the load bearing of the hind 
limbs and forces exerted is roughly half of what humans experience when walking (Taylor et 
al., 2006), which allows for comparisons of mechanical loading of implants in sheep to humans 
possible. Also, sheep have a rate of bone healing similar to humans (den Boer et al., 1999). This 
makes sheep a very useful model for femoral and tibial defect and fracture models. They have 




(Reichert et al., 2009). The creation of large segmental defects and critical sized defects are the 
most common models for sheep in orthopaedic research and a segmental defect size of 25-40 
mm and cancellous defects >11 mm in diameter, do not heal spontaneously (Ehrnberg, De 
Pablos, Martinez‐Lotti, Kreicbergs, & Nilsson, 1993; Malhotra, Pelletier, Yu, Christou, & 
Walsh, 2014; Moxham et al., 1996). Whilst sheep bones possess a similar macrostructure to 
humans, making them an ideal model, histologically, the bone structure of sheep is quite 
different. Small animals and humans are known to possess osteons or Harversian systems, that 
are the basic structural unit of compact bone (Pearce, Richards, Milz, Schneider, & Pearce, 
2007). In larger animals such as sheep, plexiform bone predominates. Plexiform bone possesses 
a dense vascular canal network, which creates a “brick-wall” appearance and provides greater 
mechanical support than woven bone (Brits, Steyn, & Noelle, 2014). Furthermore, it has been 
reported that age can play a role in the extent of bone remodelling. Skeletally immature sheep 
have shown a similar bone density to humans, compared to mature sheep which have a 
significantly higher trabecular bone density and therefore greater bone strength than humans 
(Nafei, Danielsen, Linde, & Hvid, 2000). For these reasons it is critical to ensure that the age 
of sheep used within a study are consistent and considered when making comparisons between 
other studies. Although there is no perfect animal model that can simulate identical biological, 
physiological biochemical characteristics to humans, it is possible to obtain a great deal of pre-










Peroxidases are a haem-containing superfamily of ubiquitous and essential proteins found in all 
living organisms, including plants, microorganisms, fungi and animals (Hiraga, Sasaki, Ito, 
Ohashi, & Matsui, 2001). It is well-established that these enzymes possess antimicrobial action, 
through the formation of enzymatic reaction products. The term “haem” refers to the 
ferriprotoporphyrin IX prosthetic group which is an essential component of the enzymes active 
site and essential for reactivity with hydrogen peroxide (H2O2). In the enzymes native form, the 
oxidative status of iron within the haem group is in the ferric form of Fe3+. In the presence of 
H2O2 peroxidases engage in several redox reactions which convert the enzyme into various 
catalytic intermediates (Figure 1.8). Firstly, the reaction is initiated by available H2O2 which 
results in two-electron oxidation, converting the enzyme from its native state of Fe3+ into 
Compound I (Fe4+) and the H2O2 is reduced to H2O. Compound I, which is a strong oxidant can 
be converted back to its ferric state by reacting with halide ions (X-) (“halogenation cycle”) 
(Davies, Hawkins, Pattison, & Rees, 2008). The conversion of the enzyme back to this state 
occurs via a two-electron reduction, oxidising the halide ions to the corresponding hypohalous 
acids (HOX). Additionally, Compound I can be reduced by one electron by oxidising organic 
and inorganic substrates (RH*), yielding a substrate free radical and Compound II, which is 
referred to as the oxy-ferryl (Fe4+) haem intermediate (“peroxidase cycle”). In a second one-
electron reduction step Compound II is reduced back to its resting ferric peroxidase and 
generates a free radical and water molecule. At the end of the cycle the peroxidase is returned 
to its original native state, to repeat the halogenation and peroxidase cycles through the 
initiation of available H2O2. Another intermediate, Compound III is usually formed when there 
is an excess of H2O2. This intermediate is also largely formed by the combination of superoxide, 
which is produced by the oxidation of H2O2, with the ferric enzyme (Fe
2+). Although, the 




molecular oxygen. In this state Compound III is not catalytically active, but the inactivation is 



























Figure 1.8 Catalytic cycle of peroxidases showing dual pathways of oxidation. In the 
halogenation cycle the native enzyme is oxidised in the presence of H2O2 to form Compound I 
(1). In the presence of halides (X-), Compound I is converted back its native state and, in the 
process, produces hypohalous acids (HOX) (2) (halogenation cycle). Alternatively, in absence 
of halides, Compound I can be converted to Compound II by one electron-donating substrates 
(RH*) (3) (peroxidase cycle). Compound III is formed in the presence of excess H2O2, which 
is an inactive form of the enzyme that slowly reverses back to its active native state. Figure 




















































Peroxidases and wound healing  
 There is sufficient evidence that peroxidases, specifically mammalian-derived are 
involved in inflammatory processes and therefore could have implications in wound healing. 
However, a discovery by Rayner and colleagues reported that compounds present in bovine 
milk whey growth factor extract (WGFE) have a direct effect on skin fibroblasts to increase 
tissue repair in normal and compromised models of wound healing (Rayner et al., 2000). The 
additional treatment with WGFE promoted cellular infiltration within the wound for both 
normal and steroid-treated rats compared to control (Figure 1.9), with a greater response to 
WGFE observed in the steroid-treated animals. It was first suggested that growth factors such 
as TGF-β were responsible for the enhanced wound response, however, the amount of growth 
factors that would be required to generate such a response were not present in WGFE. This led 
to the suggestion that another factor must be present to influence the difference in fibrogenic 
response. Using cell-based screening methods of fractionated WGFE, it was ascertained that 
bovine lactoperoxidase (LPO) was the protein responsible for generating the main functional 
component of WGFE. Additional research has demonstrated increased collagen production by 
dermal fibroblasts treated with mammalian peroxidases, myeloperoxidase (MPO) and 
eosinophil peroxidase (EPO) and plant-peroxidases soybean peroxidase (SBP) and horseradish 
peroxidase (HRP) (DeNichilo et al., 2015). The ability of SBP to promote a fibrogenic response 
in a full-thickness dermal porcine model further demonstrates the regenerative potential of these 
enzymes. Of significant relevance to this thesis, is their capacity to significantly increase the 
synthesis of a collagen-rich ECM which is essential for successful bone repair (Figure 1.10). 
Furthermore, the direct stimulation of fibroblasts to promote invasion, migration and collagen 
synthesis suggested that peroxidases may have a causative role on mesenchymal cellular 
function, in the context of repair. Studies have since demonstrated that MPO, EPO 




cells, including endothelial cells, by acting as pro-angiogenic molecules capable of regulating 
vessel development (Figure 1.11). These findings suggest that peroxidases, both mammalian 
and plant-derived could have applications in tissue repair, through the regulation of 
mesenchymal lineage cells essential in wound healing and be utilised as therapeutic agents in 



























Figure 1.9 Histology of a rat incisional wound model. Photomicrographs show cross sections 
through day 5 incisional wounds from normal (A and B) and steroid-treated (C and D) rats that 
received WGFE (B and D) or collagen vehicle only (A and C) at time of wounding. Sections 








































Figure 1.10 Peroxidase enzymes stimulate potent tissue regeneration in a porcine excisional 
wound model. A and B: The wounds with INTEGRA stapled in place. C and D: Representative 
low-power images of sections stained with Masson's trichrome. E and F: Representative higher-
magnification images of boxed areas in panels C and D showing the control INTEGRA is 
poorly infiltrated with cells from the wound bed (E), whereas the INTEGRA treated with SBP 
(F) shows numerous fibroblasts and inflammatory cells interspersed with new extracellular 
matrix deposited between the INTEGRA fibres. Figure adapted and modified from (DeNichilo 






































Figure 1.11 Peroxidases promote vascularisation of subcutaneously injected Matrigel in mice. 
(A) Representative images of excised Matrigel plugs stimulated with (i) saline (vehicle), (ii) 
VEGF (100 ng/ml), (iii) EPO (5 μg) and (iv) MPO (5 μg), shows an increase in vasculature in 
the peroxidase treated Matrigel. (B) Representative images of CD31 (4×) and H&E (40×) 
immunostaining of (i) saline (vehicle), (ii) VEGF (100 ng/ml), (iii) EPO (5 μg), and (iv) MPO 
(5 μg), shows peroxidase induced infiltration of endothelial cells and an increase in red blood 
cells (arrows) within the Matrigel compared to saline and VEGF controls. Figure adapted and 























 MPO is a highly cationic, dimeric protein which consists of two monomer units of 
73kDa each, joined by a cysteine disulphide bridge (Davies et al., 2008). They are located 
within neutrophils which provide the frontline of defence against invading microbes, by 
engulfing and ingesting foreign organisms. During granulocyte differentiation of 
promyelocytes and promyelomonocytes, MPO is synthesised throughout their maturation 
process in the bone marrow. The synthesis of MPO ceases after this stage of cell development 
and so circulating monocytes do not continue to synthesise this enzyme. During neutrophil 
activation and ingestion of a foreign body into a phagosomal compartment, azurophilic granules 
are secreted into the compartment, where MPO is subsequently released. Coinciding with the 
secretion of azurophilic granules, NADPH oxidase is assembled on the internal membrane 
surface and is responsible for providing a source of superoxide radicals and H2O2, which MPO 
subsequently transforms, into hypochlorous acid (Borregaard & Cowland, 1997).     
 
Eosinophil peroxidase 
 EPO is a 70kDa cationic glycoprotein, which shares a sequence homology of 70% with 
MPO, however the catalytic behaviour and substrate specificities of these enzymes differ 
(Tahboub, Galijasevic, Diamond, & Abu-Soud, 2005). It is located within the cytoplasmic 
granules of human eosinophilic leukocytes and unlike MPO is much less active in Cl- oxidation, 
but highly active with Br-, I- and SCN- (Bozeman, Learn, & Thomas, 1990). Whilst neutrophils 
phagocytose their target and release MPO into the phagolysosomal compartment, the larger size 
of parasites targeted by eosinophils requires the exocytosis release of EPO onto the parasite 
surface. Eosinophils play an essential role in allergic reactions and a major part in host defence 
against parasites, fungi and bacteria by generating superoxide anions through an NADPH 




and H2O2, with levels of these molecules estimated to be threefold to tenfold higher than those 
generated by MPO (Davies et al., 2008).  
 
Mammalian peroxidases and fracture healing 
 In the occurrence of most fractures there is a certain amount of mechanical instability 
which leads to interfragmentary movement of the bone and consequently, secondary bone 
healing. This response requires a local inflammatory reaction by circulating inflammatory cells, 
including neutrophils, eosinophils and macrophages, which remain in the fracture region until 
regenerative cells invade the site (Prasad & Udupa, 1972). This inflammatory phase becomes 
initiated when the vasculature becomes disrupted and a haematoma forms around the fracture 
site, leading to the infiltration of these cells. Within 24 hours after injury there is a significant 
influx of neutrophils, which become the predominant leukocyte at the fracture haematoma 
(Glynne Andrew, Andrew, Freemont, & Marsh, 1994). Here, the inflammatory cells release 
pro-inflammatory factors that are essential in initiating the repair cascade. They carry out this 
role by having a chemotactic effect on other inflammatory cells, enhancing ECM synthesis, 
stimulating angiogenesis and recruiting fibrogenic cells to the fracture site (Dimitriou et al., 
2005). The importance of the initial fracture haematoma and subsequent inflammatory phase 
has been demonstrated in animal models. Studies have shown that removal of the haematoma 
as well as repeated debridement of the haematoma, leads to delayed or non-union (Grundnes & 
Reikerås, 1993; Park, Silva, Bahk, McKellop, & Lieberman, 2002). MPO and EPO have not 
yet been directly implicated in the bone repair process beyond providing oxidative defence 
against bacteria and invading pathogens. However, the knowledge that these enzymes are 
released at sites of tissue injury and inflammation, suggests a potential role for these enzymes 
in the repair process. Furthermore, recent studies have demonstrated an association between 




suggesting a link between an increased presence of eosinophils and pathological osteogenesis 
(Mehta, Campeau, Kita, & Hagan, 2008; Snidvongs et al., 2012). A link between inflammatory 
involvement and ectopic bone formation has also been reported in the soft tissue of patients 
following a traumatic injury, which is defined as heterotopic ossification (HO) (Evans et al., 
2009). Whilst it is well established that inflammatory cells are a contributing factor to HO, the 
mechanisms and factors responsible are not yet defined (Convente, Wang, Pignolo, Kaplan, & 
Shore, 2015). These findings suggest that localised use of mammalian peroxidases MPO and 
EPO could potentiate the bone repair process.  
 
Soybean peroxidase 
SBP is a 37 kD glycoprotein expressed in the root, leaf and seed hull of Glycine max 
(soybean) (Gillikin & Graham, 1991). It belongs to the secretory plant peroxidase superfamily 
(class III), which play a role in the self defence system of plants, lignification (strengthening of 
the cell wall) and salt tolerance (Henriksen et al., 2001). Besides SBP, the most well-known 
member of the class III peroxidases in horseradish peroxidase (HRP), to which SBP shares 57% 
sequence homology (Welinder, Mauro, & Nørskov-Lauritsen, 1992). HRP has been identified 
as the most structurally similar protein to SBP, with key structural characteristics maintained 
between the two proteins. This includes the location of their four distinguishing disulphide 
bridges, a single tryptophan present and a prosthetic haem group (Welinder & Larsen, 2004). 
Whilst both HRP and SBP have been widely used for biosensing and diagnostic applications 
due to high stability, SBP has been recognised to be significantly more thermally stable, possess 
greater catalytic activity and is reportedly less susceptible to haem loss and permanent 
inactivation by hydrogen peroxide (McEldoon & Dordick, 1996; Wright & Nicell, 1999). The 
inactivation temperature of SBP is reportedly 90.5°C, compared to 81.5°C for HRP. 




(Henriksen et al., 2001; McEldoon & Dordick, 1996). In addition, SBP is present in large 
amounts, readily available and inexpensive, which makes it an attractive candidate over HRP 
for large scale use (Gillikin & Graham, 1991).  As expected, plant-derived peroxidases also 
differ from mammalian peroxidases in both size and binding of the haem group. Plant 
peroxidases, including SBP consist of ~ 300 amino acids and the haem-domain is not covalently 
bound, compared to mammalian peroxidases which are much larger, ranging from 576-738 
amino acids and covalent bonding of the haem group (O'Brien, 2000; Obinger, 2006). Whilst 
mammalian peroxidases have been widely studied due to their greater physiological relevance, 
plant peroxidases have been tested for use in enzymatic crosslinking of hydrogels. These studies 
have demonstrated not only resistance to hydrogel degradation after subcutaneous injection but 
also in vivo non-cytotoxicity (Sofia, Singh, & Kaplan, 2002). The advantageous properties of 
SBP, particularly its stability, has given rise to numerous medical applications, such as a 
detecting agent in diagnostic toolkits and biosensing for various medical conditions (Hiraga et 
al., 2001). Although SBP’s uses are still being fully elucidated, its superior functionality and 
availability makes it an attractive agent for further research.   
 
Oxidative stress and bone maintenance 
 It is well-established that oxidative stress is involved in mineral tissue homeostasis and 
the production of reactive oxygen species (ROS) contributes by promoting bone resorption 
through the formation and activation of osteoclasts (Ha et al., 2004). Studies using bone marrow 
precursor cells have demonstrated that RANKL-induced osteoclastogenesis requires ROS 
production. Overexpression of glutathione peroxidase 1, the main antioxidant enzyme found in 
osteoclasts, has been shown to prevent RANKL-induced osteoclastogenesis (Lean, Jagger, 
Kirstein, Fuller, & Chambers, 2005; Lee et al., 2005). This suggests a key role for H2O2 in the 




oxidative stress and inhibit osteoblast differentiation and reduce their lifespan. When mouse 
osteoblastic cells were incubated with H2O2, mineralisation levels decreased and osteogenic 
markers RUNX2, ALP and BSP decreased in expression (Arai, Shibata, Pugdee, Abiko, & 
Ogata, 2007). However, this can be overcome by the use of ROS inhibitors, which have been 
shown to restore osteoblast differentiation (A. L. Liu, Zhang, Zhu, Liao, & Liu, 2004). Whilst 
it is clear ROS production is present during normal bone remodelling, recent studies have 
shown increasing oxidative stress might be involved in the pathogenesis of some bone diseases. 
For example, postmenopausal women who are at greatest risk of developing osteoporosis, are 
found to have decreased catalase and glutathione peroxidase activity, which are critical for 
depleting H2O2 (Ozgocmen, Kaya, Fadillioglu, Aydogan, & Yilmaz, 2007). Furthermore, 
studies have shown diabetic patients who present with increased oxidative stress levels have an 
associated increase in fracture risk (Strotmeyer & Cauley, 2007). In addition to impairing these 
diseases, high levels of ROS can impede the fracture healing process, by inhibiting osteoblast 
formation. This increase in ROS cannot be depleted without the addition of antioxidant 
enzymatic activity.  Thus, current data suggest antioxidants might be beneficial in bone health 











AIMS AND SIGNIFICANCE OF THE PROJECT 
The repair of large bony defects and non-unions that arise because of bone disease, trauma or 
tumour removal remains a significant challenge for orthopaedic surgeons. The occurrence of a 
non-union that cannot heal naturally is associated with several morbidities and can lead to 
disability and consequently financial burden on both the patient and economy. Furthermore, the 
number of patients requiring treatment is increasing due to the ageing population.  To restore 
and stabilise the bone, bone grafting or the use of bone graft substitutes is required. Successful 
bone graft substitutes require three key characteristics, osteogenicity, osteoinduction and 
osteoconduction. Unfortunately, besides autologous grafting, which has several associated 
morbidities, researchers are yet to identify a graft substitute which possesses the three key 
characteristics required to successfully repair bone.  
Our laboratory has been investigating a group of enzymes called peroxidases which may 
provide osteoinductive properties, to be used in combination with scaffold materials. 
Peroxidases are haem-containing enzymes whose functional involvement in organism health 
has mainly been limited to providing a mechanism for oxidative defence against invading 
bacteria and other pathogenic microorganisms. Work published by our laboratory provides 
evidence that mammalian peroxidases MPO and EPO, and plant-derived peroxidase SBP, 
stimulate the migration of fibroblastic cells and promote their ability to secrete collagen type I 
protein both in vitro and in vivo to generate a functional ECM (DeNichilo et al., 2015). In 
addition, we have presented further evidence demonstrating the ability of peroxidases to 
promote angiogenesis and inhibit osteoclastogenesis, suggesting a potential role for these 
enzymes in fracture repair.  
 Osteoblasts are the main cell type responsible for collagen type I biosynthesis during 
normal bone formation and fracture repair. It is well established that osteoblasts, endothelial 




therefore hypothesise that peroxidase enzymes can influence osteoblast cellular processes to 
increase collagen biosynthesis and matrix mineralisation resulting in new bone formation. This 
novel concept raises the possibility that peroxidase enzymes may have therapeutic potential in 
regulating new bone formation in various clinical settings, including fracture repair and disease-
related bone loss.  
The hypothesis of this thesis is peroxidase enzymes have a causative role on osteoblast 
function, resulting in increased collagen ECM biosynthesis and mineralisation and as a result, 

















The specific aims of this research project are: 
 
Aim 1: investigate the effect of physiologically-relevant mammalian peroxidase enzymes on 
osteoblast cell functionality of collagenous ECM biosynthesis and deposition and 
mineralisation of the deposited matrix. 
 
Aim 2: explore the ability of plant-derived peroxidase enzymes to promote osteoblast 
functionality and determine their effectiveness compared to mammalian peroxidases. 
 
Aim 3: determine the osteoinductive potential of plant-derived peroxidase enzymes to 























 PEROXIDASE ENZYMES REGULATE COLLAGEN 
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MPO and EPO Stimulate Cultured Osteoblasts to Secrete Type I Collagen 













































Eosinophil Peroxidase Promotes Osteoblast Matrix Mineralization In Vitro 
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CHAPTER 3:  
SOYBEAN PEROXIDASE REGULATES COLLAGEN TYPE I 
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Large bone defects and fractures remain a significant problem in regenerative medicine. Current 
treatment strategies which include autografting, allografting or the use of synthetic materials, 
promote bone repair but have numerous limitations including, poor osteoinductive effects. 
Growth factors such as bone morphogenetic proteins (BMPs) improve osteoinduction however, 
we are yet to identify one that is of greater economic value and with fewer adverse effects. 
Peroxidases are haem-containing enzymes which are normally released at sites of tissue injury 
and inflammation by infiltrating immune cells and until recently, have been studied mainly in 
the context of providing oxidative defence against invading pathogens. We have discovered 
new and previously unrecognised roles for haem peroxidases in extracellular matrix 
biosynthesis, angiogenesis and osteoclastogenesis, all of which play an important role in bone 
remodelling and repair. In this study, we used in vitro models to investigate the ability of the 
extremely cheap, stable and potent plant-derived soybean peroxidase, to regulate osteoblast 
function, which is necessary for normal bone repair. Here, we have demonstrated soybean 
peroxidase’s pro-osteogenic role, by promoting collagen I biosynthesis and matrix 
mineralisation, which are both essential for the formation and maturation of a mineralised 
scaffold and subsequently, new bone. Mechanistically, we have also shown soybean 
peroxidase’s ability to regulate osteogenic genes responsible for inflammation, extracellular 
matrix remodelling and ossification, which are necessary for normal bone healing. These 
findings show soybean peroxidase to be an effective regulator of osteoblast function and thus, 








Large bone defects which occur as a result of trauma, tumour resection and fractures remain a 
significant problem in regenerative medicine. Autogenous bone graft transplantation is the 
current “gold standard” for the treatment of large bone defects. This form of transplantation 
consists of bone matrix, autologous cells and growth factors which provide a scaffold for new 
bone to form (Jimi et al., 2012). However, there are significant limitations associated with 
autografting including, pain from bone harvesting, longer rehabilitation and limited supply of 
grafting material (Homma et al., 2013). Despite alternatives such as allografts or synthetic graft 
materials, these treatment strategies are also limited by immunogenic or poor osteoinductive 
effects (Betz, 2002).  
Recently, synthetic biomaterials which possess osteoconductive properties that promote 
the ingrowth of newly formed bone, have been widely investigated for use in bone regenerative 
medicine (Oryan, Alidadi, Moshiri, & Maffulli, 2014). For example, β-tricalcium phosphate (β-
TCP) and synthetic hydroxyapatite (HA) are being developed due to their high biocompatibility 
and osteoconductive properties (Patlolla & Arinzeh, 2014). Despite their poor osteoinductive 
potential (e.g.; to signal stem cell differentiation), these calcium phosphate ceramics have 
proven to be effective carriers of osteoinductive agents such as bone morphogenetic proteins 
(BMPs), to accelerate bone formation (Ono, Gunji, Kaneko, Sait, & Kuboki, 1995). While 
BMPs play an important role in fracture repair, with the ability to promote recruitment, 
proliferation, differentiation and migration of bone-forming cells (Lind et al., 1996), their 
clinical use has resulted in a number of complications. These include higher revision rates, due 
to an increased inflammatory response accompanied by cyst-like bone and soft tissue swelling 
and ectopic bone formation (Zara et al., 2011). These reports, along with the significant high 
cost of using BMPs suggest the need to identify osteoinductive factors which result in fewer 




suggested to promote bone repair, such as those to enhance vascularisation (Curtin et al., 2015), 
but none have advanced to the clinic. Therefore, new therapeutic interventions for complex 
osseous defects and fractures are needed. 
Peroxidases are a group of haem-containing enzymes found in animals, plants and 
micro-organisms (Hiraga et al., 2001). It is well-established that these enzymes share the same 
catalytic mechanism, by converting hydrogen peroxide and chloride ions into hypochlorous 
acid, which is one of the most reactive oxidants produced in vivo and is responsible for 
peroxidase anti-microbial actions (Aruoma & Halliwell, 1987). We have recently discovered 
new functional roles for peroxidase enzymes, including mammalian myeloperoxidase (MPO) 
and eosinophil peroxidase (EPO), plant-derived soybean peroxidase (SBP) and horseradish 
peroxidase (HRP). These roles include the ability to regulate fibroblast collagen extracellular 
matrix (ECM) biosynthesis (DeNichilo et al., 2015), drive angiogenesis (Panagopoulos et al., 
2015) and inhibit osteoclastogenesis (Panagopoulos et al., 2017). Collectively, these findings 
suggest that peroxidases may have a causative role in tissue repair. In addition, we have recently 
discovered additional new roles for mammalian peroxidases in bone repair, by their ability to 
promote osteoblast collagen biosynthesis, osteogenic gene expression and bone matrix 
mineralisation (Mark O. DeNichilo et al., 2016). Despite the effectiveness demonstrated by 
mammalian peroxidases on osteoblast function in vitro, we have investigated the possible 
contribution of the plant-derived SBP in bone repair. SBP is one of the most biologically active 
peroxidase enzymes we have tested to-date, both in vitro and in vivo (DeNichilo et al., 2015). 
Furthermore, SBP is safe, highly stable and extremely cheap to manufacture in large quantities, 
making it a highly feasible and desirable candidate for clinical use. 
In this report, we characterise for the first time, the ability of SBP to stimulate the 
release of collagen type I and promote matrix mineralisation by primary human osteoblasts. 




to be essential for bone regeneration. Our findings show SBP promotes osteoblast function in 






















MATERIALS AND METHODS 
Ethics Statement 
The use of all normal human donor-derived bone tissue was approved by the human ethics 
committee of the Royal Adelaide Hospital/University of Adelaide (Approval No. RAH 
090101). Human bone samples were obtained with informed written donor consent, as required 
and approved by the ethics committee. 
 
Osteoblast Cell Culture 
Normal human bone-derived osteoblasts were isolated from intertrochanteric trabecular bone 
samples from four donors of both genders, age range 46-67 years, undergoing primary hip and 
knee replacement surgery, as described previously (Atkins et al., 2003). Human osteoblasts 
were expanded in culture using Dulbecco’s Modified Eagle’s Medium (DMEM; high glucose 
with no ascorbic acid; AA), supplemented with 2 mmol/L glutamine, 100 IU/mL penicillin, 100 
µg/mL streptomycin, 20 mmol/L HEPES, and 10% foetal bovine serum (FBS; Invitrogen Life 
Technologies, Carlsbad, CA) in a 5% CO2-containing humidified atmosphere. These cells 
maintain an osteoblastic phenotype in culture and stain positive for alkaline phosphatase 
activity. 
 
Collagen I Enzyme-Linked Immunosorbent Assay (ELISA) 
To evaluate the effect of SBP on collagen I production, osteoblasts were cultured and treated 
as previously described (Mark O. DeNichilo et al., 2016). Briefly, osteoblasts were cultured in 
96-well plates for 5 days in DMEM/10% FBS until reaching confluence. Cells were starved 
overnight in serum-free DMEM and then stimulated for an additional 72 h in serum-free 
DMEM containing either AA 2-phosphate at 100 µmol/L (Wako Chemical Industries, Osaka, 




Liberty, IA) in the absence of AA supplementation. Osteoblast-conditioned media was then 
collected for measurement of secreted, soluble type I collagen by ELISA. Cell viability/growth 
was then assessed using the alamarBlue fluorescent dye assay (Invitrogen Life Technologies), 
according to manufacturer’s instructions. Fluorescence was measured at wavelengths of 530 
nm excitation and 595 nm emission using a FLUOstar Optima plate reader (BMG Labtek 
Australia, Mornington, VIC). 
The amount of soluble type I collagen in cell-conditioned medium was measured by a 
direct coat enzyme-linked immunosorbent assay method, as previously described (Mark O. 
DeNichilo et al., 2016). Samples and standards were added to a 96-well Maxisorp plate (Nunc) 
and left at 4°C overnight. The plate was then washed with phosphate-buffered saline (PBS) 
with 0.05% Tween, 2.5% bovine serum albumin (BSA)/PBS blocking solution added to each 
well and the plate incubated for 1 h at room temperature. The plate was then washed and 
primary antibody (0.25 μg/mL rabbit anti-human-collagen I polyclonal; Rockland 
Immunochemicals, Limerick, PA) in 5% non-fat dairy milk added to each well for 3 h at room 
temperature. After washing, europium-tagged anti-rabbit secondary antibody (0.5 μg/mL in 1% 
BSA/PBS; Perkin Elmer Life Sciences, Turku, Finland) was added for 1h at room temperature. 
After a final wash, Enhancement Solution (Perkin Elmer Life Sciences) was added, and time-
resolved fluorescence was measured at excitation 355 nm and emission 620 nm using a 
FLUOstar Optima plate reader (BMG Labtek Australia). The collagen content of each sample 
was determined from the standard curve (μg/mL), constructed from purified type I human 
placental collagen (BD Biosciences Australia, North Ryde, NSW) and then normalised to 





In Vitro Mineralisation 
Normal human bone-derived osteoblasts were seeded into 96-well plates (Nunc) at a density of 
1.2 × 104 cells per well and cultured for 5 days in AA-free 10% FBS/DMEM at 37°C and 5% 
CO2. Triplicate wells were stimulated with SBP in osteogenic DMEM mineralisation medium 
[DMEM supplemented with 5% FBS, 100 μmol/L AA 2-phosphate (Wako Chemical 
Industries), 10−8 mol/L dexamethasone (Hospira Australia, Mulgrave, VIC), and 10 mmol/L β-
glycerophosphate (Sigma-Aldrich)] to assist bone mineral formation. Cells were maintained in 
culture for 21 days, with fresh medium with or without SBP, changed every 7 days. To detect 
matrix mineralisation, the Alizarin Red staining method was used as previously described 
(Mark O. DeNichilo et al., 2016). Briefly, cells were washed with PBS and fixed with 10% 
phosphate-buffered formalin. The fixed cells were then washed twice with distilled water and 
stained with 2% Alizarin Red S solution (Sigma-Aldrich). The stained mineralised matrix was 
photographed using a Nikon Eclipse 50i microscope attached to a DS-L2 control unit (Digital 
Sight, Nikon Europe, Amsterdam, The Netherlands) and a DS-Fi1 digital camera (Nikon 
Corporation, Tokyo, Japan).  
The extent of mineralisation was quantitated by eluting the Alizarin Red S dye with 
10% (w/v) cetylpyridinium chloride (Sigma-Aldrich) in 10 mM phosphate buffer pH 7.0, for 
10 mins to release remaining calcium-bound Alizarin Red S.  Absorbance was measured at a 
wavelength of 570 nm using a FLUOstar Optima plate reader (BMG Labtek Australia).  
 
Microarray 
To evaluate the effects on known primary human osteoblast pro-osteogenic genes by SBP, a 
microarray was performed. Osteoblasts harvested from a single donor were seeded at a density 
of 6 × 104 into T25 culture flasks in DMEM/10 % FBS and maintained in culture for 5 days. 




osteogenic DMEM mineralisation medium [DMEM supplemented with 5 % FBS, 100 μmol/L 
AA 2-phosphate (Wako Chemical Industries), 10−8 mol/L dexamethasone (Hospira Australia, 
Mulgrave, VIC), and 10 mmol/L β-glycerophosphate (Sigma-Aldrich)]. Total RNA was 
harvested using an RNeasy Mini Kit (Qiagen Australia, Chadstone, VIC) according to the 
manufacturer’s instructions. RNA yield and purity were quantified by Nanodrop 
spectrophotometric measurement at 260 nm (Nanodrop Technologies, Thermo Fisher 
Scientific, Scoresby, VIC, Australia). RNA was analysed using whole-genome Illumina 
sequencing (Australian Genome Research Facility, Parkville, VIC). The Illumina 
GenomeStudio software (Version 1.9.0) was used to extract and normalise the expression data 
for the mean intensity of the array. Genes that were statistically significant (p = ≤0.05) and 
exceeded a pre-set threshold for significantly higher (≥1.5 fold change) or lower (≤1.5 fold 
change) expression compared to control were included for further analysis. Of the genes 
presented in the array, 836 genes met this prerequisite. Those genes which had the greatest 
difference in fold change and known key osteogenic genes were selected and classified 
according to associated gene ontology terms and participation in biological pathways. The 
genes were arranged in related groups using functional annotation tools and bioinformatics 
software provided by the open web-based Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) Bioinformatics Resources 6.7 (Huang, Sherman, & Lempicki, 
2009a, 2009b) (Table 1). 
 
Quantitative Real-Time PCR (qRT-PCR) 
To validate nominated genes from the microarray, qRT-PCR was performed. Custom TaqMan® 
Array Fast Plates (Thermo Fisher, Scoresby, VIC) were pre-spotted with TaqMan® Gene 
Expression Assay probes for BMP-2, BSP, WNT-5A, FRZ-B, CCL5, CXCL5, CXCL6, 




The assay numbers for each probe are defined in Table 2. Quantitative RT-PCR was performed 
using TaqMan® Fast Advanced Master Mix (Thermo Fisher, Scoresby, VIC), in a ViiA 7 Real-
Time System (Applied Biosystems, Foster City, CA).  
 
Data Analysis and Statistics 
Data points derived from experiments are reported as the mean ± standard deviation (SD). 
Analysis of variance to determine significant difference between samples was performed using 
















SBP Stimulates Primary Human Osteoblasts to Release Type I Collagen  
Collagen type I is the most abundant type of collagen and accounts for approximately 90% of 
the total collagen content of bone (Gay & Miller, 1978). When primary human osteoblasts were 
stimulated for 72 h with SBP, in the absence of AA we observed a dose-responsive increase in 
collagen type I release. Maximal doses of SBP resulted in a three-fold increase in soluble 
collagen type I release which was comparable to the amount measured in the presence of AA, 
which was used as the control (Fig. 1A). Significant increases in collagen secretion were 
observed even at the lowest dose of SBP of 6 ng/mL. Assessment of cell viability indicated that 
SBP and AA had no impact on osteoblast numbers (Fig. 1B), even up to 6.25µg/mL (data not 
shown). This confirmed that SBP is not toxic at the doses tested and importantly, shows the 
increase in collagen type I was not related to effects on cellular proliferation. Consistent with 
our previously published data of mammalian peroxidases, these results demonstrate that the 
plant-derived SBP can promote collagen type I secretion by osteoblasts in an ascorbic acid-
















Figure 1. Soybean peroxidase (SBP) promotes collagen I release by cultured human 
osteoblasts. A ELISA detection of soluble collagen I in osteoblast-conditioned medium after 
72h stimulation with SBP at the doses indicated. Ascorbic acid 2-phosphate (AA) at 100µmol/L 
served as the positive control, whereas cells treated with Dulbecco’s modified Eagle’s medium 
(DMEM) alone (unstim) served as the baseline control. The levels of collagen I are expressed 
as fold change and normalised so the average values of unstim were set to 1. The data are pooled 
from three experiments each conducted using cells derived from two donors. B Viability of 
cultured osteoblasts after 72h stimulation as assessed using the alamarBlue dye assay. Cell 
viability was normalised so the average values of unstim cells were set to 100% relative to each 
peroxidase dose. The data are pooled from three experiments each conducted using cells derived 
from three donors. Data are the mean±SD for unstim, AA, and each peroxidase dose. *P < 0.05; 







































































































SBP Stimulates Primary Human Osteoblasts to Promote Matrix Mineralisation 
We next examined the ability of SBP to promote the matrix mineralisation process of primary 
human osteoblasts. Light microscopy clearly shows SBP significantly increased mineral 
deposition of osteoblasts at each dose tested (Fig. 2A), as observed by the increased intensity 
of Alizarin Red staining from the lowest dose at 0.78 µg/mL. Quantification of the eluted 
Alizarin Red staining revealed that the addition of SBP resulted in a significant increase in 
mineralisation at 0.78 µg/mL (Fig. 2B), with cells stimulated by SBP at the highest dose of 6.25 
µg/mL showing a three-fold increase in mineral deposition. This was compared to cells 
maintained under mineralising conditions without SBP. Together, these data suggest that SBP 




















Figure 2. Soybean peroxidase promotes osteoblast matrix mineralisation in vitro. A 
Representative images of Alizarin Red stained cultured human osteoblasts stimulated with SBP 
for 21 days at the various doses indicated. B Quantitation of mineralised calcium extracted from 
cultured osteoblast monolayers following stimulation with SBP for 21 days at the doses 
indicated. Cells treated with mineralisation medium alone (unstim.) served as the baseline 
control. The levels of mineralised calcium are expressed as fold change and normalised so the 
average values of unstim were set to 1. Statistical significance was calculated by two-tailed 
Student’s t test with the various doses of SBP compared to the mineralisation medium alone 
(unstim) group. Dose response experiments using osteoblasts were independently performed at 
least three times using cells derived from two different donors. Data are the mean ± SD of 
































SBP Regulates Expression of Genes Involved in Osteoblast Function 
We next sought to attribute the effects of SBP on mineralisation to levels of expression of genes 
associated with osteoblast differentiation and mineralisation. We performed a RNA microarray 
on SBP-treated osteoblasts which identified 6,554 genes to be differentially expressed. Those 
genes which had the greatest difference in fold change and known key genes involved in 
osteoblast function were selected and classified according to the molecular function of their 
related protein and their involvement in biological processes, using web-based classification 
programs as described in the Methods section. Based on that approach we present differentially 
expressed genes in six categories: genes involved in ossification, inflammatory and immune 
responses, cell migration, extracellular matrix and genes encoded in response to wounding 
(Table 1.). The expression of selected genes was confirmed by qRT-PCR. The data obtained 
with qRT-PCR confirmed the microarray data on gene expression for BMP-2, BSP, WNT-5A, 
FRZ-B, CCL5, CXCL5, CXCL6, CXCL12, MMP1, MMP3, IL-6 and IL-8 (Table 2.). Taken 
together, these results indicate the effects of peroxidases may be the culmination of differential 





























Term Count Genes Fold 
enrichment 
GO:0001503~ossification 2 BSP, BMP2,  29.40 
GO:0006954~inflammatory response 5 IL6, BMP2, IL8, CXCL6, CCL5 18.92 
GO:0006955~immune response 6 IL6, IL8, CXCL5, CXCL6, CXCL12, CCL5 10.69 
GO:0009611~response to wounding 5 IL6, BMP2, IL8, CXCL6, CCL5 11.60 
GO:0016477~cell migration 4 IL6, IL8, CXCL12, CCL5 17.82 



















Gene Assay number PCR product size (bp) Fold change SD p-value 
BMP-2 Hs00154192_m1 60 4.87 0.93 0.001993 
BSP Hs00173720_m1 95 4.31 0.11 0.000001 
WNT-5A Hs00998537_m1 61 2.21 0.04 0.000012 
FRZ-B Hs00173503_m1 108 0.44 0.01 0.000012 
CCL5 Hs00982282_m1 70 208.67 4.75 0.000001 
CXCL5 Hs01099660_g1 93 461.44 31.25 0.000014 
CXCL6 Hs00605742_g1 125 649.20 77.15 0.000130 
CXCL12 Hs03676656_mH 88 5.11 0.40 0.000063 
MMP1 Hs00899658_m1 64 26.08 0.98 0.000002 
MMP3 Hs00968305_m1 126 403.35 17.89 0.000003 
IL6 Hs00174131_m1 95 5.41 0.27 0.000011 
IL8 Hs00174103_m1 101 147.57 9.46 0.000011 





Collagen type I is the major extracellular matrix constituent of bone and its synthesis by 
osteoblasts is critical for normal bone formation (Cox, Einhorn, Tzioupis, & Giannoudis, 2010). 
It is well reported that AA, an enzymatic cofactor, is essential for the accumulation of a 
collagen-rich matrix which subsequently becomes mineralised (Franceschi & Iyer, 1992). The 
role of AA in ECM production has been well characterised, by its ability to promote 
hydroxylation of peptidyl-proline which results in the assembly of a stabilised triple-helical 
procollagen molecule. Without AA, the absence of hydroxylation results in unstable 
procollagen molecules which rapidly degrade within the cell (Myllyharju & Kivirikko, 2001). 
Importantly, in vivo studies have shown that AA deficiency results in delayed bone matrix 
mineralisation (Sugimoto et al., 1998), highlighting the link between collagen deposition and 
matrix mineralisation. We show here that the plant-derived SBP stimulates collagen I release 
by osteoblasts in the absence of AA supplementation. When considering the previously 
assumed, indispensable role of AA in ECM production and mineralisation, the ability of SBP 
to elicit a similar response in collagen synthesis in the absence of AA suggests a potential 
therapeutic role for this enzyme in regenerative medicine.  
We demonstrate here that SBP promotes osteoblast matrix mineralisation. For these 
mineralisation studies, AA was maintained in the mineral media due to its essential role for 
normal cross-linking of soluble collagen and its presence in normal physiological conditions 
(Peterkofsky, 1991). In the presence of AA, we found SBP to significantly promote matrix 
mineralisation by human osteoblasts. When considering the limitations of current grafting 
strategies, particularly the healing time required for large bone defects, we believe SBP could 
be effective at accelerating the repair process as seen by the increase in mineralisation compared 




stage of collagen biosynthesis suggests that SBP possesses the necessary properties of an 
effective osteoinductive agent.   
In association with mineralisation, we found SBP to be an effective regulator of several 
genes involved in osteoblast function including, osteoblast differentiation, mineralisation and 
repair. Firstly, our in vitro studies exhibited significant up-regulation of BMP-2, WNT-5A and 
BSP. It was previously reported that BMP-2 regulates BSP and WNT-5A mRNA expression 
by cultured osteoblasts (Lecanda, Avioli, & Cheng, 1997; Robubi et al., 2014). SBP not only 
up-regulated these bone forming genes but down-regulated a known repressor of osteogenesis, 
FRZ-B related protein. FRZ-B acts as a competitive inhibitor of the WNT signalling pathway 
(S. W. Cho et al., 2008), which, like BMP-2 is a key modulator of bone formation (Takada, 
Kouzmenko, & Kato, 2009). These data suggest that SBP may indirectly regulate mineralisation 
via induction of BMP-2, which acts as an intermediate for the regulation of downstream effector 
genes. BMP-2 has been extensively tested both in vitro and in vivo as an agent for the repair of 
osseous defects both alone and in combination with other growth factors (Nakamura et al., 
2005; Simmons, Alsberg, Hsiong, Kim, & Mooney, 2004; Street, Bao, Bunting, et al., 2002). 
Of these, vascular endothelial growth factor (VEGF) has been highly investigated by its ability 
to induce angiogenesis, act as an effective promoter of osteoblast differentiation and BMP-2 
induced bone formation (Peng et al., 2005; Street, Bao, Bunting, et al., 2002). This is of 
particular relevance given our recently published findings which demonstrate the pro-
angiogenic potential of peroxidases compared to VEGF (Panagopoulos et al., 2015).While 
BMP-2 appears to be the most potent osteoinductive agent identified to-date, several studies 
have shown osteoclastic activation and bone resorption in response to BMP-2 treatment 
(Seeherman, Li, Bouxsein, & Wozney, 2010; Toth et al., 2009), which may interfere with 
accelerated bone repair. This is further supported by a recent study which tested osteoprotegerin 




the differentiation and function of osteoclasts, increased bone repair of a mouse critical defect 
model in combination with locally delivered BMP-2 (Bougioukli et al., 2016). These reports 
are of significant interest, considering our recent findings which demonstrate the ability of 
peroxidases to inhibit RANKL-induced osteoclast formation and bone resorption 
(Panagopoulos et al., 2017). Therefore, our findings suggest that peroxidases may act as 
effective agents in regulating multiple aspects of the bone regenerative process.  
 In addition to the regulation of genes involved in osteoblast function by SBP, we 
observed significant up-regulation of numerous cytokines and chemokines including CCL5, 
CXCL5, CXCL6, CXCL12, IL-8, and IL-6, which are crucial in the recruitment and regulation 
of bone remodelling. For example, CCL5 when knocked out in mice, resulted in impaired bone 
formation and increased osteoclastogenesis (Wintges et al., 2013). Moreover, CCL5, was 
shown to promote osteoblast migration and survival (Yu, Huang, Collin‐Osdoby, & Osdoby, 
2004). The regulation of  IL-8, CXCL5 and CXCL6, which are essential for endothelial cell 
proliferation and neutrophil attraction (Koch et al., 2001), further supports SBPs potential role 
in angiogenesis. The pro-inflammatory cytokine IL-6 was also upregulated by SBP, which has 
been shown to both enhance and inhibit osteoclastogenesis and more recently has been reported 
to be involved in promoting osteoclastogenesis by indirectly increasing RANKL expression by 
osteoblasts (Duplomb et al., 2008; Udagawa et al., 1995). However recent studies have found 
IL-6 may affect bone mass by influencing osteocyte communication towards osteoblasts 
(Bakker, Kulkarni, Klein-Nulend, & Lems, 2014). Despite the conflicting results it is evident 
IL-6 is necessary for bone remodelling and therefore essential in the repair process. Up-
regulated CXCL12 is also substantially involved in bone formation and healing. Previous 
studies have shown that blocking CXCL12 or its receptor CXCR4, led to reduced osteoblastic 
differentiation markers, including their transcription factors (Zhu et al., 2007). Furthermore, in 




density and decreased expression of collagen type I (Zhu, Liang, Huang, Doty, & Boskey, 
2011). Interestingly, increased collagen type I secretion in the presence of SBP may be 
responsible for the increase in MMP1 expression observed, due to its functional role in the 
degradation of collagen type I (Rao, Mohanam, Puppala, & Rao, 1999). Although MMP3 is not 
a collagenase like MMP1, it was reported previously to be an effective activator of proMMP1 
(Rao et al., 1999). This investigation of the mechanistic relationship SBP has on osteoblast 
function was only conducted on a handful of key osteogenic genes, in order to better understand 
the role SBP has on mineralisation and repair. The limitation of only investigating a handful of 
key genes does provide preliminary evidence to suggest a causative role of SBP in the bone 
regenerative process by mechanisms involving the regulation of genes essential for bone repair.    
 In conclusion, our findings suggest SBP possesses a new pro-osteogenic role, to act as 
an osteoinductive agent, by promoting collagen I biosynthesis and matrix mineralisation. We 
have also presented the first evidence for potential mechanisms, demonstrating SBP’s ability to 
regulate genes involved in osteoblast function that are responsible for inflammation, ECM 
remodelling and ossification, which are necessary for normal bone healing. However, further 
studies are required to fully elucidate the mechanisms by which SBP promotes osteoblast 
differentiation and activity. Although it remains to be seen how effective SBP will be in vivo, 
we believe that it has the potential to be used in a localised setting in combination with current, 
commercially available biomaterials and scaffolds. Continued research both in vitro and in vivo 
will further optimise SBP and ultimately determine its potential as an effective osteoinductive 
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Recently, the use of synthetic scaffolds to provide a three-dimensional platform for bone cells 
to integrate and deposit new bone for the treatment of bone defects has increased, in particular 
as carriers of osteoinductive factors. However, despite on-going research we are yet to identify 
an ideal factor that can provide controlled, accelerated regeneration of new bone without the 
limitations in current regenerative therapies. The aim of the present study was to investigate 
whether SBP possesses osteoinductive capabilities by accelerating bone repair when combined 
with commercially available biphasic calcium phosphate (BCP) granules. BCP granules were 
pre-treated with SBP and untreated BCP served as the control. The ability for SBP to promote 
bone repair beyond the capacity of BCP granules alone was evaluated by conducting 
microcomputed tomography and histological analyses after 4 weeks of implantation in the 
femoral condyles of 4 sheep, using a bilateral model. Micro-CT analysis revealed SBP-treated 
BCP significantly increased bone formation within the defects at 4 weeks compared to BCP 
alone. Histological assessment correlated with reconstructions from micro-CT data, showing 
new bone formation prominent at the defect margins and surrounding individual BCP granules. 
In addition, a significant presence of osteoblasts and embedded osteocytes were observed in all 
specimens, indicative of intramembranous ossification. Whilst this study only assessed a single, 
early time point, results showed that SBP may be beneficial to be used clinically as an 










Bone grafting is a common procedure in orthopaedic surgery to repair large osseous defects and 
fractures as a result of damaged, diseased or aged skeletal tissues. It is estimated that 2.2 million 
bone grafting procedures are performed annually world-wide and these figures are expected to 
double by 2020 due to population aging (Biancamaria Baroli, 2009; Giannoudis et al., 2005).  
 Clinically, autografting remains the current ‘gold standard’ grafting procedure for 
treating bone defects as it is histocompatible and non-immunogenic (Bauer & Muschler, 
2000a). Autograft bone is also highly effective due to its three-dimensional scaffold structure, 
which provides osteoconduction and also by providing bone cells for osteogenesis and growth 
factors (ie. BMP-2) to augment osteoinduction (Finkemeier, 2002). However, the amount of 
autologous bone which can be harvested is very limited and there is the potential for donor site 
morbidity at the second surgical site and higher complication rates (Almaiman, Al-Bargi, & 
Manson, 2013; Finkemeier, 2002; Gamradt & Lieberman, 2003). Allografting is a common 
alternative to standard autografting as it can provide ample amounts of bone without the 
additional morbidities from harvesting, however it also possesses a number of limitations 
(Gazdag, Lane, Glaser, & Forster, 1995). These include loss of osteoinductive properties and 
cellular components due to processing of bones to avoid immunologic rejection, as well as the 
risk of infection and disease transmission (Bostrom & Seigerman, 2005; Greenwald et al., 
2001). Due to these limitations the use of bone graft substitutes, often in the form of calcium 
phosphate ceramics is increasing, by their ability to eliminate many of the issues associated 
with the use of autologous and autograft bone (Fillingham & Jacobs, 2016). Of these, synthetic 
materials comprised of β-tricalcium phosphate (β-TCP) and hydroxyapatite (HA), termed 
biphasic calcium phosphate (BCP) have been studied extensively (Bouler, Pilet, Gauthier, & 
Verron, 2017) as the composition of these minerals is comparable to normal bone tissue (Kivrak 




properties, new bone formation is often limited due to their poor osteoinductive capabilities 
(Yuan et al., 2002). This limitation can be overcome however, by the incorporation of 
osteoinductive agents such as BMP-2 (Szpalski et al., 2012). Unfortunately, there are numerous 
concerns associated with the application of BMP-2, including local complications such as 
ectopic bone formation and significant costs attributed to the high doses administered 
(Tannoury & An, 2014). Therefore, researchers are currently investigating other growth factors 
and agents that possess osteoinductive properties which can effectively repair bone similarly to 
BMP-2, without producing comparable adverse effects. 
  Our laboratory has recently identified new functional roles for a group of haem-
containing enzymes called peroxidases. These enzymes which are naturally occurring in many 
organisms such as animals, plants and microorganisms have been well reported to possess 
antimicrobial activity (Aruoma & Halliwell, 1987). However, we have recently discovered that 
these enzymes, specifically mammalian peroxidases myeloperoxidase (MPO) and eosinophil 
peroxidase (EPO) and additionally plant peroxidases horseradish peroxidase (HRP) and 
soybean peroxidase (SBP) possess the ability to regulate various processes critical for tissue 
repair. These include the ability to regulate fibroblast ECM collagen biosynthesis (DeNichilo 
et al., 2015), drive angiogenesis (Panagopoulos et al., 2015) and inhibit osteoclastogenesis 
(Panagopoulos et al., 2017). Additionally, in the context of bone repair we have presented 
evidence that our most potent peroxidases tested to date, EPO and SBP, significantly regulate 
osteoblast ECM collagen biosynthesis and matrix mineralisation in vitro (unpublished). These 
findings demonstrate a potential role for peroxidases to be used as osteoinductive agents for 
bone repair. Although EPO has proven to be highly effective in regulating osteoblast function, 
it is highly expensive and currently not available in large quantities, making the use of EPO 
impractical for clinical use. Therefore we have been focusing our research on plant-derived 




vitro and in vivo (DeNichilo et al., 2015), but importantly it is non-toxic, highly stable and very 
inexpensive to manufacture. These properties make it an attractive agent, with significant 
potential for translation. However, before we can consider their use clinically, we needed to 
assess the ability of SBP to repair bone in vivo. 
Therefore, the objective of this preliminary study was to evaluate the osteoinductive 
capacity of SBP to accelerate bone regeneration when used in combination with a commercially 
available BCP. For this purpose SBP-soaked BCP granules (15:85 HA:β-TCP) were implanted 
in a critical-sized defect of the sheep femoral condyle. The use of a bilateral model allowed for 
individuals to serve as their own control, receiving ceramic granules alone or in combination 
with SBP. New bone formation was assessed 4 weeks post-surgery by histological and 
microcomputed tomography analyses. Our data demonstrate preliminary osteoinductive effects 














MATERIALS AND METHODS 
Ethics Statement 
The study was approved by the Animal Ethics Committee of the University of Adelaide (M-




Four male castrated, wethers sheep aged 3-5, years weighing 56-69 kg (mean: 60; SD ± 5.9) 
were randomly assigned with even distribution, to receive the experimental treatment in either 
the left or right hind limb to eliminate bias. The opposing hind limb received the control 
treatment. Due to the comparatively low impact this procedure has on the animal, a bilateral 
model is well tolerated and allows for the control and experimental treatments to be conducted 
in each animal.  
 
Experimental Procedure 
The sheep were fasted for 12 h prior but had free access to water during this time. To alleviate 
post-operative pain, a fentanyl patch (2-3 µg/kg/hr) was applied 24 h prior to surgery and 
reapplied every 72 h for a minimum of 10 days. After pre-emptive sedation and analgesia with 
midazolam (0.2 mg/kg) and buprenorphine (0.005 mg/kg), animals were induced with Propofol, 
which was administered until effect (3-4 mg/kg). Animals were then intubated and administered 
Isoflurane in oxygen at 2%. A patient warmer was used during the procedure to keep the 
animal’s body temperature stable and to prevent hypothermia. Cephalosporin (22 mg/kg) and 
Meloxicam (0.2 mg/kg) were administered pre-emptively and during the surgical procedure. 




Animals were positioned in dorsal recumbency and the operative site for each hind limb was 
prepared through sequential sterilising scrubs and draping. 
 Once marked, a 2-3 cm incision was made directly over the mid-medial aspect of the 
femoral condyle and underlying soft tissue removed to reveal the bone. A 12 mm diameter, 10 
mm deep defect was then created with sequential use of differing size drill heads (8.5 mm, 10 
mm and 12 mm). This method was used to avoid unnecessary thermal necrosis. The defect was 
then flushed with saline to remove any remaining bone fragments. Once the defect was created, 
commercially available Mastergraft® BCP [15% HA / 85% β-TCP] granules (Medtronic 
Sofamor Danek, Memphis, TN) were deposited into either condyle. In one defect, 1.25 cc BCP, 
which was pre-soaked for 15 mins in 5 mL soybean peroxidase (650 µg/mL) was added. The 
remaining defect received 1.25 cc BCP pre-soaked with 5 mL Ringer’s lactate (saline) solution 
as the control. Once the soaked BCP granules were added, they were gently compacted into the 
defect to ensure consistent and even distribution. The wound was closed using 0-vicryl in a 
cruciate pattern for the deep fascial layer and continuous pattern for the subcutaneous layer. 
Metallic skin staples were then applied over the surface. Finally, a bandage with antimicrobial 
dressing was applied over the surgical site. Animals were given antibiotics and analgesics 
according to the standard operating protocols. Animals remained in a sling for 24 h before being 
moved to indoor housing for the entirety of the study. Sheep were monitored 3 times a day for 
the first 3 days followed by once per day for the remainder of the study. Bandages were removed 
2-3 days post-surgery and surgical wounds assessed for signs of wound complication. The skin 
staples were removed 14 days post-surgery. The animals were sacrificed 4 weeks post-surgery 






Microcomputed Tomography (Micro-CT) Imaging 
Samples (n=4) in 70% ethanol were cut to size in order to fit within a 36.9 mm diameter sample 
tube with the drill hole defect in vertical orientation. The samples were scanned in a micro-CT 
scanner 40 (Scanco Medical, Bassersdorf, Switzerland) at an energy of 70 kVp and intensity of 
114 µA with 200 µs integration time, resulting in an isotropic voxel size of 36 µm. The 
reconstructed scans were evaluated using Scanco µCT Evaluation Program (v6.5-3). A 
cylindrical volume of interest (VOI) with a diameter of 11 mm was defined for the analysis. 
The vertical evaluation length (cylinder height) was defined in a preview and consisted of the 
central, cylindrical section of the defect (approximately 100 slices or 3.6 mm), excluding the 
zones at the top and bottom ends of the defect to prevent “boundary effects”. To identify newly 
formed bone throughout the VOI, and to reduce partial volume effect at the grain boundaries of 
the ceramic granules, a masking procedure was employed (Burghardt, Kazakia, Laib & 
Majumdar, 2008). First, using a high threshold of 5069 Hounsfield Units (HU, 872.6 mg 
HA/mm3), with a gauss filter of σ=0.8 and a support of 1.0 was applied to segment the BCP 
granules within the defect. Next, the granules were enlarged by 2 voxels on all faces, and this 
enlarged granule volume was deducted from the VOI, leaving only the intra-granule space of 
the VOI. Newly formed bone was segmented from this space with a lower threshold of 2121 
HU (356.3 mg HA/mm3), a gauss filter of σ=1.8 and a support of 3.0. For the quantitative 
evaluation, the total cylindrical volume of interest (TV), the volume of the segmented newly 
formed bone (BV) and the average mineral density of the newly formed bone were calculated.  
 
Histology 
Femoral condyles were subjected to ethanol dehydration steps prior to being placed into a 
Methyl Methacrylate (MMA): Polyethylene Glycol 400 (PEG) solution (100% MMA: 10% 




was induced using a solution containing MMA: PEG: Perkadox (0.2%). Trimmed resin blocks 
were sectioned in the sagittal plane at 10 μm thickness. Sections were prepared for Toluidine 
blue staining. Images were taken using the NanoZoomer Digital Pathology (NDP-Hamamatsu, 
Hamamatsu City, Japan). Toluidine blue stained slides were used to visualise sites of new bone 
formation and the presence of osteoblasts and osteocytes. Sections were viewed using the 
associated software (NDP View Version 2.5; Hamamatsu, Hamamatsu City, Japan). 
 
Statistical Analysis  
Data points derived from experiments are reported as the mean ± standard deviation (SD). 
Analysis of variance to determine significant difference between samples was performed using 














Based on previous in vitro and in vivo studies (unpublished), we selected SBP at 650 µg/mL 
for in vivo testing in a standardised bilateral femoral defect model (Fig. 1). Saline and 
peroxidase-soaked BCP granules were prepared (Fig. 2) and implanted directly into the defect 
site (Fig. 3). No surgical complications or postoperative morbidities were detected in any of the 
sheep. The impact of this procedure on the animals’ wellbeing, in particular, ambulation has 

























Figure 1. Surgical procedure: an incision is created from the condylar notch to the proximal 
trochlear ridge (solid line). The osteochondral defect (diameter 12mm, depth 10mm) is created 
in the medial aspect of both femoral condyles (bilateral model) and is controlled by a drill guide 


























































































Figure 3. Scaffold implantation (a), soft compaction into the defect (b) and after compaction 


























The effects of SBP in combination with biphasic ceramic granules on bone formation after 4 
weeks of implantation were studied by micro-CT imaging. Representative three-dimensional 
reconstructions of the micro-CT images which were created in the central zone of the defect 
(Fig. 4) showed increased bone formation in the treatment hind limbs, compared to control (Fig. 
5A). Quantitative analysis of the reconstructions depicted in Fig. 5A revealed a statistically 
significant increase in bone volume at the defect site in the SBP-treated limbs compared to 

























Figure 4. Representative micro-CT image of reconstructed defect block used for quantification. 
A cylindrical volume of interest (VOI) with a diameter of 11 mm and length of 3.6 mm, 
























Figure 5. Localised application of SBP-soaked BCP granules within a femoral defect increases 
bone formation. Sheep received a 12mmx10mm defect within the femoral condyle of both hind 
limbs. Each defect was filled with saline or SBP pre-soaked granules. A: Representative micro-
CT reconstructions. At 28 days the sheep were sacrificed, and micro-CT scanning of the bones 
was performed at the defect site. B: Quantitative analysis of the micro-CT data showed 
increased bone volume within the defects treated with BCP+SBP compared to BCP+saline 
(control). Analysis is presented as the mean bone volume (BV) to tissue volume (TV) of the 
SBP treatment compared to control. Data was analysed and reported as the mean ± standard 
deviation (SD). Analysis of variance to determine significant difference between samples was 
performed using the paired Student’s t-test of four determinations for control and peroxidases. 


































In conjunction with micro-CT evaluation, histological assessment of new bone formation in the 
presence of SBP compared to control was conducted. Toluidine blue staining of cross-sections 
through the cancellous bone and implant showed an observable increase in new bone formation 
at the defect margins (data not shown). However, this increase in new bone formation at the 
periphery was not uniform around the entire implant in both SBP-treated defects and control. 
Representative images (Fig. 7) of new bone formation for each sample was shown to occur 
around individual HA/β-TCP Mastergraft® (MG) BCP granules. However, no difference in the 
extent of new bone formation around individual BCP granules between SBP-treated and saline-
treated control was observed. Despite no observable difference in bone formation around 
individual BCP granules, it is evident that SBP-treated granules did not impair normal bone 
formation processes. This can be deduced by the presence of osteoblasts and osteocytes adjacent 
to the treated granules in all animals tested (Fig. 7). Thus, observational analysis of histological 


















Figure 7. Toluidine blue staining demonstrates formation of new bone after localised treatment 
of SBP-soaked Mastergraft® granules at 28 days post-surgery. Representative histological 
analysis of sheep femoral defects after 28 days treated with saline or SBP-soaked HA/β-TCP 
Mastergraft® (MG) BCP granules. Each individual animal has its own representative image for 
SBP and saline (a-b; c-d; e-f; g-h). Each representative image was taken near the defect margin 
where majority of new bone growth had occurred. Yellow asterisks indicate bone formation 
adjacent to BCP granules. Voids marked with a “G” indicate the location of MG granules. 
Cuboidal osteoblasts (dark blue) lining the new bone forming surface are indicated by red 















































In this proof-of-concept study, the ability of SBP to accelerate bone repair in combination with 
commercially sourced BCP was assessed. The study successfully showed new bone formation 
after 4 weeks of BCP implantation, with increased healing observed in the bone defects treated 
with SBP.    
The critical-sized femoral condyle defect model remains a suitable model for testing the 
effectiveness of osteoinductive factors. The decision to use sheep for testing SBP’s 
osteoinductive capabilities was due to its reliability as a representative pre-clinical model to 
assess new bone formation (Apelt et al., 2004; Peters, Hines, Bachus, Craig, & Bloebaum, 2006; 
Theiss et al., 2005). It has been well reported that sheep possess a similar bone metabolism to 
humans and the ability to create larger defects in sheep to test therapies is of greater relevance 
than the use of rodents (N Patel et al., 2005).  
 The role that peroxidases have in regulating multiple cell types to promote tissue 
regeneration has been well-reported by our laboratory (DeNichilo et al., 2015; Panagopoulos et 
al., 2015). Of particular relevance to this study are our recent findings which have demonstrated 
that SBP is highly effective at stimulating primary osteoblasts to promote collagen biosynthesis 
and mineralisation of the deposited ECM (unpublished). The results presented in this current 
study, predominantly the significant increase in new bone formation as shown by micro-CT (p 
= 0.04), successfully validates this previously conducted in vitro data. These in vitro studies 
also presented early mechanistic evidence showing significant regulation of a number of key 
osteogenic genes. This further supports the rapid new bone deposition observed in this study 
and clearly demonstrates SBP’s potent osteoinductive capabilities. In addition, the mechanistic 
data also demonstrates upregulation of a number of pro-inflammatory genes in the presence of 
SBP, including a number of MMP’s and chemokines. Whilst the upregulation of these genes, 





repair (Pape et al., 2010) would be beneficial, we must consider the potential risk of long-term 
inflammatory responses as a result of treatment with SBP, particularly in bone defects. 
Therefore, investigating late stage bone formation, specifically the integrity and strength of new 
bone after treatment with SBP is necessary for future studies.  
 From our in vitro studies and the broader research community, it is well established that 
peroxidases have a pro-inflammatory role, which could be beneficial for fracture healing. 
However, the significant increase in bone formation observed by this micro-CT at just four 
weeks post-surgery suggests a potential role for these enzymes not just for repair of non-unions, 
but also large bony defects. Furthermore, observational assessment of this preliminary study 
shows osteoblasts lining the deposited osteoid, with osteocytes entrapped within their lacunae. 
Signs of endochondral bone formation, such as the presence of chondrocytes or cartilage were 
absent. In regions of direct bone-implant contact at the defect margin, moderate bone ingrowth 
was observed. However, there were minimal regions of direct bone-implant contact at the defect 
margins (data not shown) which is potentially the cause of non-uniform bone formation at the 
periphery of the defects in all specimens. This observation correlates with the micro-CT 
reconstructions, where majority of new bone is at the defect margins, in a non-uniform 
distribution. The nature of the highly porous structure of the individual BCP granules created 
difficulty in ensuring the implant was uniform throughout the defect. Compaction of the 
granules once in the defect was conducted in an attempt to overcome this potential problem, 
however, to ensure granule pores remained intact, they were not compacted with significant 
force. It could be argued that an implant with direct bone-implant contact, such as a smooth 
press-fit implant would allow for greater uniformity in new bone formation at the defect margin. 
However, it has been reported that the addition of HA can eliminate the negative response of 
non-interference fit between bone and the implant (Søballe, Hansen, Brockstedt-Rasmussen, 





demonstrated an ability for SBP to promote new bone formation compared to BCP alone. In 
addition, the presence of SBP does not appear to generate a toxicity effect to the local cell 
population, where we see an abundance of osteoblasts and osteocytes, necessary for normal 
bone healing. Whilst this proof-of-concept study was successful, numerous limitations must be 
considered.   
A limitation of this study was the number of animals used. When considering the 
literature, there is significant variability in sheep numbers when using the critical-sized femoral 
condyle defect model (Milano et al., 2010; Zscharnack et al., 2010). Whilst most studies range 
from 6-12 animals, using a bilateral model, some studies only use 4 animals per treatment. 
However, this study was conducted as a preliminary, proof-of-concept study and so no prior 
study power was determined. Despite this, a significant difference between the addition of SBP 
compared to BCP alone was observed. The positive result suggests future studies will not 
require significantly large numbers to obtain a conclusive result, however careful consideration 
will be needed due to the intent to optimise SBP for clinical use. An additional consideration 
for future in vivo studies is the use of non-steroidal anti-inflammatory drugs (NSAIDs). These 
drugs have been previously reported to impair bone healing however, the drug Meloxicam, used 
in this study reportedly has no effect of bone healing (Pountos, Georgouli, Calori, & 
Giannoudis, 2012). Furthermore, a decrease in healing was not observed in the SBP-treated 
group, suggesting that the NSAIDs used in this study did not inhibit the bone reparative effects 
of SBP. Future fracture studies where callus formation and inflammation are critical for 
successful healing should consider which NSAIDs are used and how this may affect the pro-
inflammatory effects of peroxidases, including SBP. An aspect of this study which could also 
be considered a limitation is the single and early endpoint used to assess the effectiveness of 
SBP to accelerate the bone repair process. The single, short time point of 4 weeks was proposed 





bone environment. This early time point also enabled us to observe potential toxicity effects 
exhibited by the peroxidases at such a high concentration. Sampling across multiple time points 
at 2, 4, 6 and 12 weeks would have provided a more revealing image of the true bone formation 
and remodelling processes in the presence of SBP. A robust study of this nature would provide 
an understanding of where the agent is acting in the repair process and whether it provides any 
benefit in reducing healing time. However, with limited resources we were only afforded a 
single time point. An additional limitation to our analysis of the overall healing response was 
the limited histological data. Whilst observational assessment correlated with our micro-CT 
analysis, the use of double-labelled fluorochromes would enable us to directly measure the 
extent of new bone formation. Future studies will also be better equipped to conduct robust 
histomorphometrics with blinded analysis. A further limitation for this study is the absence of 
a positive control (ie. BMP-2). Future studies will require the comparison of SBP to the 
previous standard, BMP-2 to discern the clinical potential of SBP. Although this study does not 
allow us to compare to a positive control, the purpose of this study was to provide evidence that 
SBP can promote bone repair in vivo, when used in combination with an appropriate scaffold, 
which has been successfully demonstrated. 
 In conclusion, the present study provides a proof-of-concept role for peroxidases, by 
demonstrating that SBP, in combination with commercially available BCP could accelerate the 
repair of a critical-sized femoral condyle defect in sheep.  
Furthermore, histological observations between SBP and control suggest that SBP is 
non-toxic to the local cell populations, which is a critical step when identifying new, 
experimental agents. The requirement for novel osteoinductive agents to replace BMP-2 in the 
clinic provides an opportunity to continue to explore the possible applications of SBP in repair. 
Based on the limitations drawn from this study, further studies with more robust analyses are 





includes testing SBP long-term, in large segmental defect and fracture models with comparisons 
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CHAPTER 5:  
SOYBEAN PEROXIDASE IN THE REPAIR OF CALVARIAL 
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To date, the functional role of peroxidase enzymes in human health has mainly been limited to 
providing a mechanism for oxidative defence against invading bacteria and other pathogenic 
microorganisms. Our laboratory has recently discovered new and important roles for 
mammalian and plant-derived peroxidases that include, the ability to promote tissue 
regeneration by modulating the function of mesenchymal lineage cells. This suggests that they 
may be used to repair bone defects and fractures. We previously demonstrated that SBP has the 
capacity to enhance bone repair in an ovine critical size defect (CSD) model. Whilst we have 
successfully established the CSD model in sheep, future fracture models testing SBP will be 
determined firstly in rodents. Therefore, this study was undertaken to validate plant-derived 
soybean peroxidase (SBP) in a mouse CSD model, which has been used extensively to test new 
bone graft substitutes. Critical size (3 mm) calvarial defects were created in the right parietal 
bone of adult female Balb/C mice. Defects were either treated with a collagen scaffold alone, 
or a scaffold pre-loaded with SBP at three separate doses (50µg, 100µg & 200µg). At 8-weeks, 
implants were retrieved and evaluated by micro-CT and histological analysis. Contrarily to 
what was expected, micro-CT results showed inhibition of bone formation in the SBP-treated 
groups when compared to scaffold alone (p < 0.01). Histological analysis revealed that for all 
SBP-treated groups at 8-weeks, the majority of the defect contained dense and slightly 
vascularised fibrous tissue. Mature bone formation was observed in the scaffold alone group 
with many positive TRAP-stained osteoclasts present, which is indicative of bone remodelling. 
For the doses investigated, the results show that the addition of SBP compromised bone 
remodelling in this mouse CSD model. These results suggest that further investigation is 
required to determine how SBP regulates cells essential for the remodelling process and further 







The repair of large or complex bone defects and fractures that cannot repair correctly require 
the use of bone graft substitutes, in order to stabilise and restore bone integrity. To successfully 
qualify as a bone graft substitute the material should ideally possess two of the following 
characteristics, osteogenicity, osteoconductivity or osteoinductivity (Lane & Sandhu, 1987). 
The current standard surgical strategies to repair skeletal defects is to utilise autogenous or 
allogenic bone materials (Bauer & Muschler, 2000b; Boyce, Edwards & Scarborough, 1999). 
Although these current approaches are generally successful, there are a number of 
disadvantages. Autologous bone is often limited in availability and complications which can 
arise in 30% of cases have numerous associated morbidities (Amini, Laurencin, & Nukavarapu, 
2012; Banwart et al., 1995; Jimi et al., 2012). Allogenic bone grafts overcome some of the 
disadvantages of autogenous bone, however the risk of disease transmission and decreased 
biological capacity compared to autografts makes them an unfavourable choice (Lane & 
Sandhu, 1987; Oklund et al., 1986). Thus, there is a requirement for alternative bone graft 
substitutes which possess or combine the aforementioned characteristics, needed to ensure 
effective bone healing.  
 Growth factors and proteins have been increasingly used and tested to act as 
osteoinductive agents for clinical use. Much focus has been on factors directly responsible for 
the regulation of numerous cellular functions, including the formation and resorption of bone. 
Bone morphogenetic proteins (BMPs), which are essential factors for promoting the activity of 
bone-forming cells, have been used extensively both pre-clinically and clinically and have 
demonstrated significant osteoinductive potential (Dragoo et al., 2003; Kloen et al., 2003; 
Mussano et al., 2007). However, there are now emerging reports of complications post-surgery 
and along with the significant high cost of using BMPs clinically, there is a need to identify 





 Our laboratory has recently demonstrated that peroxidases, which are a ubiquitous 
group of haem-containing enzymes, known for their antimicrobial role during host defence 
(Hiraga et al., 2001) have implications in wound healing (Rayner et al., 2000). Previous in vitro 
studies have demonstrated that peroxidases are pro-angiogenic (Panagopoulos et al., 2015) and 
have the capacity to stimulate osteoblasts to increase collagen I biosynthesis and mineralise the 
surrounding extracellular matrix (ECM) (DeNichilo et al., 2016). In vivo, our laboratory has 
also demonstrated that plant-derived soybean peroxidase (SBP), which is an inexpensive and 
highly available peroxidase compared to previously tested peroxidases, stimulates a fibrogenic 
response and induces connective tissue regeneration in a porcine model (DeNichilo et al., 2015). 
Additionally, we have successfully employed a CSD model in the medial femoral condyles of 
sheep (unpublished), which has demonstrated that SBP successfully accelerates bone formation 
in a critical size sheep femoral defect. This study established the clinical potential of SBP in a 
femoral drill-hole defect model, however, we needed to further optimise and verify its 
effectiveness to repair bone fractures. Although sheep are an ideal model for testing bone repair 
therapies in a fracture setting, there are significant costs associated and ethical pressures, which 
must be taken into consideration when testing new treatments (Martini, Fini, Giavaresi, & 
Giardino, 2001). In comparison, the significantly lower cost of rodents allows for high 
throughput optimisation studies. This includes the ability to conduct longitudinal studies and 
assess multiple doses. Furthermore, the size of rodent bones allows for rapid analyses compared 
to sheep. Thus, the decision was made to use of rodents as the species for preliminary testing.  
We attempted to mimic the response observed in the sheep model by exploring a critical size 
defect (CSD) model in mice. CSDs are defects which cannot heal by bone formation throughout 






 In this study we hypothesised that delivery of SBP in combination with an 
osteoconductive, absorbable collagen scaffold, CollaCote™ would increase bony bridging and 
bone formation at 8 weeks, when compared with scaffold alone. To test this hypothesis, we 
implanted SBP-loaded scaffolds into a mouse cranial CSD of 3 mm in diameter and quantified 
new bone formation at 3 days and 8 weeks by longitudinal microCT analysis. Histological 





MATERIALS AND METHODS 
Ethics Statement 
The use of all normal human donor-derived bone tissue was approved by the human ethics 
committee of the Royal Adelaide Hospital/University of Adelaide (Approval No. RAH 
090101). Human bone samples were obtained with informed written donor consent, as required 
and approved by the ethics committee. The animal study was approved by the Animal Ethics 
Committees of the University of Adelaide (M-2013-221A) and SA Pathology (8-15a).  
 
Cell Culture 
The osteosarcoma cell line SaOS-2 were kindly donated by TGR BioSciences (TGR 
BioSciences Pty Ltd, Adelaide, SA). SaOS-2 cells were expanded in culture using Dulbecco’s 
Modified Eagle’s Medium (DMEM; high glucose with no ascorbic acid; AA), supplemented 
with 2 mmol/L glutamine, 100 IU/mL penicillin, 100 µg/mL streptomycin, 20 mmol/L HEPES, 
and 10% foetal bovine serum (FBS; Invitrogen Life Technologies, Carlsbad, CA) in a 5% CO2-
containing humidified atmosphere. These cells maintain an osteoblastic phenotype in culture 
and stain positive for alkaline phosphatase activity. 
 
Cell Viability 
To determine the effects of SBP on cell viability, SaOS-2 cells were cultured in 96-well plates 
(Nunc, Roskilde, Denmark) at a density of 1.2 × 104 cells per well for 5 days in DMEM/10% 
FBS until reaching confluence. Cells were starved overnight in serum-free DMEM and then 
stimulated for an additional 72 h in serum-free DMEM containing either AA 2-phosphate at 
100 µmol/L (Wako Chemical Industries, Osaka, Japan) as a positive control, or with soybean 
peroxidase (SBP; Bio-Research Products, North Liberty, IA) in the absence of AA 





assay (Invitrogen Life Technologies), according to manufacturer’s instructions. Fluorescence 
was measured at wavelengths of 530 nm excitation and 595 nm emission using a FLUOstar 
Optima plate reader (BMG Labtek Australia, Mornington, VIC). 
 
Animals 
56 Female Balb/C mice at 8 weeks of age (Institute of Medical and Veterinary Services 
Division), weighing 13.6-23.6 g (mean: 19.9; SD ± 1.7) were acclimatised to the animal housing 
facility for a minimum period of 1 week before the commencement of experimentation. The 
general physical well-being and weight of animals were monitored continuously throughout the 
experiments. All mice were housed under pathogen-free conditions and all experimental 
procedures on animals were carried out with strict adherence to the rules and guidelines for the 
ethical use of animals in research and were approved by the Animal Ethics Committees of the 




Scaffolds used in this study were collagen-based biodegradable scaffolds called CollaCote™ 
(Medtronic Australasia, Sydney, NSW). Before conducting the in vivo study, it was confirmed 
that this scaffold material could readily uptake SBP to the desired concentrations of 50µg, 
100µg and 200µg. These doses were determined to be suitable based on previous in vitro studies 
and an in vivo pilot study. For in vitro assessment, the CollaCote™ material was cut as 3-mm 
diameter discs, using a manual biopsy puncture (Stiefel Laboratories, Melbourne, VIC). It was 
determined that each scaffold could hold 15 µl of solution. From this information, scaffolds 
were individually added to wells containing 30 µl of SBP at 3.33 mg/mL, 6.66 mg/mL and 





respectively. Scaffolds were maintained at room temperature for 24 h. Total concentration of 
SBP taken up by the scaffolds was quantified using the Nanodrop spectrophotometric 
measurement at 403 nm (Nanodrop Technologies, Thermo Fisher Scientific, Scoresby, VIC). 
For in vivo preparation, scaffolds were cut as 3-mm diameter circles in a sterile setting 
and maintained under sterile conditions. 24 h before surgery and implantation, 14 scaffolds per 
treatment group were loaded individually into separate wells of a v-bottom 96-well plate. 30 µl 
of SBP at concentrations of 3.33 mg/mL, 6.66 mg/mL and 13.33 mg/mL were aliquoted onto 
each scaffold which would result in the final concentrations of SBP within each scaffold to be 
50 µg, 100 µg and 200 µg. As a control, 30 µl of saline was also added to individual scaffolds. 
Scaffolds were loaded, sealed and kept at the IMVS Animal House at room temperature 
overnight, ready to be implanted the next day.   
 
Mouse Calvarial Critical Size Defect Model 
An established gold standard mouse calvarial size defect (CSD) model was used to test the 
ability of SBP-soaked collagen scaffolds to induce bone repair, as previously described with 
minor modifications (Aalami et al., 2004; Hollinger & Kleinschmidt, 1990). Briefly, each 
treatment group (n=14) which consisted of 8-week-old Balb/C female mice, were anaesthetised 
by 80 mg/kg Ketamine hydrochloride and 10mg/kg Xylazine via intraperitoneal (i.p) injection, 
followed by subcutaneous (s.c) injection of 0.1 mg/kg Buprenorphine analgesic. Once mice 
were non-responsive to paw pinching, hair on the scalp was clipped and disinfected with 70% 
ethanol before a C-shaped incision of the skin was made, over the right parietal bone. The 
pericranium was removed by blunt scraping and 3-mm calvarial defects were created in the 
right parietal bone with a biopsy puncture (Stiefel) with meticulous care taken to avoid 
damaging of underlying dura mater. Care was also taken to ensure the cranium did not dry out 





with a 3-mm-diameter CollaCote™ collagen scaffold (Zfx Australia Pty Ltd, Sydney, NSW), 
with the assigned treatment as mentioned above. The skin was sutured closed using resorbable 
sutures and mice were moved to a heat pad to recover before being transferred into cages. Mice 
were monitored twice a day for 5 days after surgery to ensure complete recovery. 
 
In Vivo Live Microcomputed Tomography Imaging 
Computed tomography (CT) images were obtained using a SkyScan-1076 in-vivo micro-CT 
scanner (Bruker-micro-CT, Kontich, Belgium) while the animals were anaesthetised via i.p 
injection, as previously described (Zinonos et al., 2009). Briefly, the micro-CT Scanner was 
operated at 50 kV, 110 μA, rotation step of 0.8, 0.5-mm Al filter, scanning width of 35 mm, 
scanning resolution of 9 μm, and imaging time of 30 min. For ex vivo analysis, skulls were 
surgically resected before being inserted into the scanner. Micro-CT settings remained 
consistent to the in vivo scans. The cross-sections were reconstructed using a Skyscan 
reconstruction program (software NRecon, Bruker). Cross-section images were then realigned 
consistently between samples and the sagittal sections saved (software Data Viewer, Bruker). 
Files were then imported into CTAn software (Bruker) for three-dimensional analysis and 
three-dimensional image generation. All images were viewed and edited using CTVol (Bruker) 
visualisation software. 
 
Ex Vivo Micro-CT Imaging  
At 56 days post-surgery, mice were euthanised by CO2 gas and cervical dislocation. Mice heads 
were then surgically excised and placed into labelled containers filled with 70% ethanol ready 
for ex vivo micro-CT. The micro-CT scanner and analysis was conducted as previously 






Skulls were fixed in 10% (v/v) buffered formalin (24 hours at 4°C), followed by 4 to 6 weeks 
of decalcification in 0.5 M EDTA–0.5% paraformaldehyde in PBS (pH 8.0) at 4°C. Complete 
decalcification was confirmed by radiography. The calvaria and underlying brain tissue was 
excised and then embedded in paraffin. 5 µm longitudinal sections were prepared and stained 
with hematoxylin and eosin (H&E). Additional sections were used for TRAP (Sigma-Aldrich) 
staining following the manufacture's protocol. Images were taken using the Olympus CKX41 
(Olympus, Hachioji-shi, Tokyo) microscope.  
 
Statistical Analysis 
Data points derived from experiments are reported as the mean ± standard deviation (SD). 
Analysis of variance to determine significant difference between samples was performed using 















SBP promotes cell survival at high concentrations. 
Assessment of cell viability after 72 h indicated that high dose SBP had no impact on SaOs-2 
cells when compared to untreated cells (Fig. 1). This confirmed that SBP is not toxic at the high 
doses tested and without effect on cell proliferation. This is consistent with our previous in vitro 



























Figure 1. High dose SBP does not affect cell viability. Viability of cultured osteosarcoma cell 
line SaOS-2 after 72h stimulation with SBP (µg), as assessed using the alamarBlue dye assay. 
Cell viability was normalised so the average values of untreated cells were set to 100% relative 
to each dose of SBP. Representative data are the mean ± SD of triplicate determinations, of 

































































CollaCote possesses favourable characteristics as a vessel to contain SBP.  
Visualisation of CollaCote™ under SEM shows a highly porous, honeycomb-like structure 
within the material (Fig. 2A). Interior sections showed a uniform framework of Type I bovine 
collagen with voids ranging from approximately 10 µm to 100 µm. When the scaffold material 
was cut to 3-mm diameter discs and 15 µl of SBP added at increasing concentrations, we 
observed an ability of the CollaCote™ to retain the entire 15 µl solution by swelling in size and 
increasing in colour intensity with each increasing SBP concentration (Fig. 2B). Once we were 
confident that SBP could be absorbed by the material and retained, we assessed the ability of 
the material to take up desired concentrations of SBP for implantation into mice. We confirmed 
that the scaffolds, which hold 15 µl of solution, could successfully uptake our desired doses of 
SBP to be used in vivo of 50 µg, 100 µg and 200 µg by adding SBP at 3.33 mg/mL, 6.66 mg/mL 
and 13.33 mg/mL respectively, by Nanodrop quantification of remaining solution (Fig. 2C). 
From these in vitro experiments we were confident that CollaCote™ was a suitable material to 
contain SBP and to be utilised as an osteoconductive scaffold to assist SBP in accelerating the 


















Figure 2. CollaCote readily uptakes desired concentrations of soybean peroxidase. A: 
Representative SEM images of the CollaCote scaffold material. Images were taken of the 
interior and cross-sectional aspects of the material at low and high magnifications. B: 
Representative images of CollaCote scaffolds retaining SBP at increasing concentrations. 3-
mm diameter scaffolds were cut and pre-soaked with SBP for 24 h at the doses indicated. C: 
Quantitation of SBP retained within the scaffolds after 24 h. 3-mm diameter scaffolds were 
soaked in SBP for 24 h at 3.33, 6.66 and 13.33 mg/mL. Experiments were independently 
performed two times and each reading was taken in duplicate. Data are the mean ± SD of 



















































































SBP-loaded CollaCote scaffolds inhibit bone remodelling in a Calvarial critical size defect 
model.  
Previous in vitro studies conducted by our laboratory have shown SBP to be highly effective in 
promoting the production of procollagen I and generating a mineralised ECM by primary 
human osteoblasts (unpublished). Furthermore, we have demonstrated that SBP has the 
capacity to increase the deposition of new bone at 4 weeks, in an ovine defect model. To further 
optimise and validate the effectiveness of SBP in bone and fracture repair using rodents as an 
extremely cheap and high throughput species, we needed to establish the gold-standard CSD 
model in mice. Representative micro-CT images via 3D reconstruction at day 3 post-surgery 
demonstrate consistent creation of the defects across each tested group including control (Fig. 
3A). 3D modelling and quantitative analysis of the defects containing saline-treated 
CollaCote™ at day 56 confirmed the osteoconductive ability of the scaffold material. Bone 
formation presented as total bone volume (BV), showed an approximately 50% increase in BV 
at day 56 compared to baseline (p < 0.05) (Fig. 3B). In support of the micro-CT data, 
histological evaluation confirms the presence of new bone formation, by CollaCote™ alone, as 
indicated by the formation of bone marrow pockets, angiogenesis and new bone surfaces (Fig. 
4). Furthermore, TRAP staining provided further evidence of new bone formation and 
remodelling due to the number of positive-stained osteoclasts lining the new bone surfaces. In 
contrast, SBP-loaded scaffolds significantly inhibited bone formation compared to control and 
demonstrated a BV comparable to baseline (p > 0.05). In addition, Histological evaluation of 
the maximal dose of SBP administered (200µg) showed significant reduction in bone formation 
and remodelling when compared to the saline control (Fig. 4). H&E staining shows a lack of 
newly formed bone and bone marrow pockets within the defect. A large amount of irregular 
collagen fibres can be observed within the defect surrounding small blood vessels. Finally, a 





along the original bone surfaces. These findings demonstrate the complexity of bone formation 
and remodelling and furthermore, the numerous potential roles SBP has on the regulation of 












Figure 3. SBP combined with CollaCote inhibits bone regeneration within a calvarial critical 
size defect. Mice (n=14) received a 3-mm defect within the right parietal bone of the calvarium. 
Each defect was filled with saline or SBP-soaked collagen scaffold (CollaCote). A: 
Representative micro-CT reconstructions. At day 3 live micro-CT scanning of the calvarium of 
each mouse was conducted to establish a baseline. At day 56 mice were sacrificed and ex vivo 
micro-CT scanning of the defect site was performed. B: Quantitative analysis of the micro-CT 
data showed increased bone volume within the defects treated with CollaCote+saline (control) 
compared to CollaCote+SBP at each dose. Analysis is presented as the mean bone volume (BV) 
of each SBP dose compared to control. Data was analysed using paired Student’s t-test and are 












































































Figure 4.  Reduced detection of TRAP-positive osteoclasts and bone formation in the presence 
of SBP-loaded scaffolds. A: Representative images of histological analysis using H&E and 
TRAP to visually compare between the calvarial CSD treated with SBP (200µg) and control. 






















































The purpose of this study was to establish a cheaper and high throughput model of bone repair 
by using rodents, which can be used to further optimise SBP as an osteoinductive agent. 
Therefore, the objective of this study was to evaluate the efficacy of SBP in combination with 
an osteoconductive scaffold to accelerate repair of a 3 mm critical size bone defect in mice.  
Based on our previously successful ovine model (unpublished), we hypothesised that the 
delivery of SBP, which would act as an osteoinductive agent with an osteoconductive scaffold, 
would result in a synergistic response to increase bone formation within the CSD compared to 
the scaffold alone.  
We have previously demonstrated in an ovine CSD model, that SBP is an effective agent 
at accelerating bone formation in combination with an osteoconductive scaffold. However, 
whilst the CSD model is an established model for assessing the regenerative potential of bone 
graft substitutes (Hollinger & Kleinschmidt, 1990), the mechanism of repair within these 
cancellous bone defects is predominantly via direct intramembranous ossification (Pobloth et 
al., 2016; Uebersax, 2008). This mechanism of repair differs to the combination of 
endochondral and intramembranous ossification observed in fracture models and so, new bone 
graft substitutes need to be verified in different models which replicate these mechanisms. We 
therefore aim to assess the potential of SBP to enhance repair of a fracture model initially in 
rodents, before progressing to sheep. However, the purpose of this study was to firstly establish 
SBP in a rodent model, by using a CSD model in the mouse calvaria. It was hypothesised that 
the calvarial CSD would reproduce what was observed in the sheep drill-hole CSD, due to the 
comparable healing mechanisms of intramembranous ossification (Alberius & Johnell, 1991).  
Due to this understanding, we anticipated similar outcomes in the context of bone 
formation using the mouse CSD model. In contrast, micro-CT and histological analysis showed 




between long and flat bones have previously shown that the rate of healing in long bones occurs 
much more rapidly and the absence of mechanical loading within the calvaria can impede the 
healing process (Lim et al., 2013). Whilst this was initially overlooked in our study design, the 
presence of new bone within the scaffold alone group in this study clearly demonstrates that the 
model itself may not be the problem. We are certain the collagen scaffold itself is 
osteoconductive and responsible for the partial healing of the defect, as previous experiments 
conducted in our group revealed that empty defects were generally filled with fibrous tissue 
within the 8-week timespan and absent of new bone. The 8-week timespan was selected based 
on previous studies that have shown the critical time of healing is between the 4th and 8th week 
post-surgery, with minimal healing beyond the 8-week time point (Cooper et al., 2010).  
The use of carriers for sustained release of growth factors is necessary for delivering 
bone-inducing agents. In addition, they act as osteoconductive scaffolds to provide structural 
support for the infiltrating bone-remodelling cells (Wang & Yeung, 2017). Type I collagen 
scaffolds are an ideal candidate for the delivery of growth factors, as type I collagen is a major 
component of bone (Glimcher & Lian, 1989). Collagen sponges have been extensively tested 
and have demonstrated successful release of growth factors, including BMP-2 (Friess, Uludag, 
Foskett, Biron, & Sargeant, 1999; Schmidmaier, Schwabe, Strobel, & Wildemann, 2008). In 
this study, CollaCote firstly proved to be a suitable scaffold by its ability to take-up desired 
concentrations of SBP. Secondly, it appeared to be nearly completely resorbed by 8-weeks. 
Interestingly, in the SBP-treated defects, there is a significant amount of collagen within the 
defect. It is likely that the dense collagenous tissue is unresorbed CollaCote, due to the absence 
of remodelling.  
The successful partial healing in the control group and the intact dura mater observed 
in each treatment group and animal, which is critical for normal bone repair (Cooper et al., 




inhibition of bone formation within the CSD. Recent unpublished evidence by our laboratory 
has demonstrated that SBP can effectively promote osteoblast function by increasing collagen 
biosynthesis and matrix mineralisation. With comparable results also observed in the presence 
of mammalian peroxidases (DeNichilo et al., 2016). However, we have also recently 
demonstrated that both plant and mammalian peroxidases can inhibit osteoclastogenesis in vitro 
(Panagopoulos et al., 2017). Whilst we have investigated both osteoclasts and osteoblasts in the 
context of peroxidase treatment, we have not yet investigated the effect these enzymes have in 
a dynamic co-culture system. Since bone remodelling and repair is a dynamic process which 
requires communication between both cell types (Sims & Gooi, 2008), it is possible the doses 
of SBP used disrupted this cellular communication and consequently the remodelling process.   
It is also a possibility that the absence of healing was partially related to the model itself. 
From the literature it is clear that peroxidases are released at sites of tissue injury by 
inflammatory cells, including neutrophils, macrophages and eosinophils (Acharya & 
Ackerman, 2014; Van der Veen, de Winther, & Heeringa, 2009). Furthermore, we have since 
presented in vitro evidence that plant-derived SBP promotes the expression of pro-
inflammatory markers, expressed by osteoblasts necessary for recruitment and remodelling, 
(unpublished). This suggests that peroxidases may play a greater role at sites of inflammation. 
This is of relevance to the absence of healing observed in this study, as controlled surgeries 
created in the calvaria, such as the CSD model, would not be expected to generate the same 
inflammatory response generated in the long bones, where the previous CSD model in sheep 
was conducted (unpublished). It is therefore a possibility that for peroxidases to work 
effectively as regenerative agents, a significant inflammatory response may be required. 
Inflammation does not solely provide a reason for the inhibitory effect observed in this study. 
However, since during normal fracture repair, eosinophils, neutrophils and macrophages are 




peroxidases the fracture setting likely represents the best therapeutic approach for SBP in bone 
repair. It is also well reported that peroxidases, particularly SBP, are highly stable under a range 
of temperatures and pH (Henriksen et al., 2001; McEldoon & Dordick, 1996) which suggests 
that it is unlikely SBP degraded once at the defect site.  
 Several limitations need to be considered when interpreting the data presented here. 
Firstly, the absence of a positive control such as BMP-2 would have provided valuable 
information regarding the effectiveness of SBP compared to the current clinical agent. Although 
SBP impeded the repair process, future experiments should include BMP-2 to provide more 
information as to the reliability of this model. A further limitation of this study was the lack of 
in vitro evidence to determine the suitable dose of SBP to be used. To address this, three 
increasing doses of SBP were used, however the range of doses were broad and for future 
experiments smaller doses should be considered. In addition, studies should have been 
conducted to assess the release of SBP from the scaffold material, to determine the rate and 
concentration of release. Furthermore, whilst these doses of SBP were tested in the SaOS-2 
osteosarcoma cell line, which demonstrated a nontoxic effect of these cells, validation of 
toxicity effects at high doses should be tested using primary human osteoblasts. Finally, we 
have evidence of SBP’s ability to promote osteoblast function and inhibit osteoclastogenesis, 
which suggests a role for this enzyme in bone repair when optimised. However, further in vitro 
studies are essential to understand the inhibitory effect observed in this study and should be 
conducted before pursuing the fracture model. 
Taken together, the results of this present study demonstrate an inhibition of bone 
formation following delivery of SBP within the bone defects. Despite the results of this study, 
the model was conducted successfully and CollaCote™ proved to be a suitable osteoconductive 
scaffold, by partially healing the bone defects. Moreover, SBP does not cause cytotoxicity, 




validated using primary human osteoblasts. Based on previous in vitro studies and the 
successful sheep CSD model the potential for SBP to act as an osteoinductive agent should not 
be disregarded, despite the results of this study. Therefore, future studies using rodents as a 
cheap and high-throughput model should investigate lower range doses of SBP. The link 
peroxidases have with inflammation also suggests that the fracture setting would be a more 
appropriate model to explore, compared to the calvarial CSD model where inflammation is 
limited. Whilst there is still a considerable amount of research to be done, the requirement for 
novel osteoinductive agents is clear, due to the current complications associated with the use of 
BMP-2. Therefore, further research is essential, to fully elucidate the mechanistic role of SBP 
in promoting osteoblast function and confirm whether SBP can be used as a cheap, stable and 
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The work reported in this thesis provides new contributions to knowledge on the ever-
expanding function of peroxidase enzymes and their role in health and disease. The data 
presented shows for the first time the potential of these enzymes to be used as therapeutic agents 
to promote bone repair. Specifically, mammalian and plant-derived peroxidase enzymes EPO 
and SBP respectively, potently stimulate ECM biosynthesis and mineralisation of the bone 
matrix through regulation of osteoblast activity. In view of these findings, the link between 
inflammatory cells and heterotopic ossification (HO) identifies a potential role for peroxidase 
inhibitors in reducing unwanted pathological bone formation.    
Despite current treatment strategies, including autologous grafting for bone repair and 
regeneration, researchers are yet to identify an agent that possesses the key characteristics of an 
optimal bone graft material. To date, autologous grafting remains the only material that 
provides osteoconductive, osteoinductive and osteogenic capabilities. Tissue engineering is 
considered an alternative grafting strategy due to the reduction in patient morbidities which 
commonly arise from autologous and allografting materials. This strategy comprises of 
biodegradable scaffold materials which are combined with inductive biomaterials, cells or 
growth factors to promote the repair process. Whilst a substantial amount of research has 
centred on the use of factors that promote osteogenic responses, there is great interest in 
investigating the importance of an inflammatory cell presence to improve healing (Bastian, 
Koenderman, Alblas, Leenen, & Blokhuis, 2016; Spiller et al., 2014). The initial acute 
inflammatory phase is critical for bone healing because it acts as the primary source of 
cytokines, chemokines and growth factors to the damaged site. However, the mechanisms by 
which these signalling cascades initiate bone repair are unclear. What is clear is the crosstalk 
between inflammatory cells and cells related to bone healing and remodelling is necessary, but 
also highly complex (Mountziaris, Spicer, Kasper, & Mikos, 2011). The importance of the 




influencing the regenerative process. Our laboratory has recently established that peroxidase 
enzymes, including, MPO and EPO, released by inflammatory cells that amass at sites of 
infection or trauma within the skeleton, act as regulators of fibroblast collagen ECM 
biosynthesis, angiogenesis and osteoclastogenesis. These studies provide insight into the 
potential role inflammatory cells and peroxidases play in normal tissue regeneration and fibrotic 
disease. Therefore, this thesis explored the role of peroxidases in promoting osteoblast 
functionality and bone repair. The findings presented in this thesis, identifies for the first time 
new and previously unrecognised roles of mammalian and plant-derived peroxidase enzymes 
as regulators of osteoblast functionality. To my knowledge this is the first report that describes 
a functional role for peroxidase enzymes in promoting osteoblast function and bone repair. 
The first aim of this project was to assess the effect of mammalian peroxidases MPO 
and EPO on osteoblast functionality in vitro and to establish the role these enzymes have in 
bone formation. When osteoblasts were treated with MPO or EPO in the absence of AA, we 
observed a significant increase in collagen I biosynthesis without a corresponding increase in 
collagen I mRNA levels. Inhibition of collagen I secretion by peroxidase-treated osteoblasts in 
the presence of prolyl hydroxylase inhibitor DMOG, also indicated that post-translational 
modifications were likely affected by the peroxidases. Importantly, the work presented here 
also demonstrates that MPO and EPO can be bound and internalised by osteoblasts. This 
supports previous studies demonstrating their ability to bind and be internalised by members of 
the MSC family, including fibroblasts and endothelial cells. In the presence of AA, EPO alone 
significantly promoted matrix mineralisation and regulated mRNA expression of osteogenic 
genes. These findings, together with recent data linking eosinophilia and ectopic bone 
formation (Macias et al., 2001; Snidvongs et al., 2012), collectively suggests a mechanistic 
explanation for the pro-osteogenic properties of eosinophils and a role for EPO in bone repair. 




osteogenic genes examined. Despite both MPO and EPO sharing a 70% structural homology, 
the catalytic behaviour, substrate specificities and kinetics of these enzymes differ significantly. 
Furthermore, MPO and EPO generate different intracellular oxidant species (Borregaard & 
Cowland, 1997; Bozeman, Learn, & Thomas, 1990), which could be responsible for the 
difference in their ability to promote mineralisation and regulate osteogenic gene expression. A 
recent review has highlighted the importance of MPO released by neutrophils and macrophages 
in the progression of heterotopic ossification (HO) (Kraft et al., 2016). They hypothesised that 
neutrophils may be involved in the early stages of HO as neutrophils are a major source of 
prostaglandin E2 (PGE2). PGE2 has been the target of clinical utility including fracture healing 
and osteoporosis due to its diverse actions on inflammation, bone healing and bone formation 
(Li, Thompson, & Paralkar, 2007).  The authors reported that the role of neutrophils in HO is 
due to enhanced prostaglandin E2 (PGE2) released from these cells, which leads to a dose-
dependent increase in BMP-2 and osteoblast differentiation. This increase in PGE2 is reportedly 
due to a MPO-dependent mechanism, whereby MPO transforms prostaglandins to inactive 
products and consequently alters their activity at an inflammatory site (Paredes & Weiss, 1982). 
Whilst we did not observe a response in mineralisation by MPO-treated osteoblasts in this 
thesis, the association of inflammatory MPO and bone formation will need to be further 
explored, including its role in HO. The presence of eosinophils and neutrophils in inflammatory 
diseases collectively highlights a potential mechanistic link for MPO and EPO in diseases of 
chronic inflammation. These findings present an opportunity to explore the use of peroxidase 
inhibitors as a therapeutic strategy, using models of osteitis and ectopic bone formation. 
Importantly, in vitro data to address this aim, demonstrates the capacity of EPO to regulate 
osteoblast activity, including mineralisation and osteogenic expression, which are critical 




peroxidases regulate osteoblast function we may identify multiple therapeutic strategies where 
peroxidases may be used to regulate bone formation.  
An important goal for bone repair strategies is to identify potent agents that possess 
controlled osteoinductive and/or osteogenic capabilities. The intent for these agents is to be 
utilised with osteoconductive materials, to provide surgeons with an effective synthetic bone 
graft substitute. Osteoconductive scaffolds are currently available for clinical use, however the 
identification of effective osteoinductive and osteogenic agents is still required. A critical aspect 
for a successful clinical agent, aside from its bone repair capabilities is the cost, due to the 
unavoidable expense of orthopaedic surgery. Furthermore, agents need to demonstrate potency 
and safety to ensure effective repair with minimal adverse effects. We have now demonstrated 
that the mammalian peroxidase EPO, regulates osteoblast functionality and promotes the 
cellular processes required for bone formation, including collagen I biosynthesis and matrix 
mineralisation.  However, EPO is an impractical candidate due to the prohibitively expensive 
and large-scale manufacturing costs. Conversely, the plant-derived peroxidase SBP, is 
inexpensive, commercially available in large quantities and has demonstrated potency in 
promoting collagen I section by fibroblasts and drive angiogenesis. The highly stable nature of 
SBP and its lack of toxicity in previous studies, attest to the safety of such an agent for clinical 
utility (DeNichilo et al., 2015; Hiraga, Sasaki, Ito, Ohashi, & Matsui, 2001; Panagopoulos et 
al., 2015).  
Therefore, the second aim of this project was to investigate the ability of plant-derived 
peroxidase SBP, an inexpensive and nontoxic factor, to promote osteoblast functionality as a 
potential therapeutic candidate. In vitro experiments presented in this thesis demonstrated that 
SBP stimulated collagen I release by osteoblasts, promoted mineralisation of the deposited 
ECM and concomitantly regulated mRNA expression of numerous key osteogenic genes. SBP, 




positive control, AA (Ch. 3, Fig. 1). In addition, osteoblasts stimulated with SBP under 
mineralising conditions showed up to a 3-fold increase in ECM mineralisation (Ch. 3, Fig 2), 
similarly to what was observed in the presence of EPO (Ch. 2, Fig. 5). Whilst EPO demonstrated 
greater potency at maximal doses of up to 6-fold, under the same mineralising conditions, the 
effectiveness of SBP, combined with its numerous benefits, including low cost, availability and 
stability suggests this enzyme could be an effective and economic therapeutic agent. The 
greatest variability between EPO and SBP was the mRNA expression level of BMP-2. EPO 
showed ~14-fold increase in expression (Ch. 2, Fig. 6) compared to a near 5-fold increase 
observed in the presence of SBP (Ch. 3, Table 2). The comparable mRNA expression of 
downstream genes regulated in the presence of SBP and EPO, including WNT-5A and BSP, 
suggests that a minimal increase in BMP-2 expression is evidently sufficient to promote 
expression of downstream targets. Therefore, the reduced BMP-2 expression of SBP-treated 
osteoblasts is still sufficient to significantly promote mineralisation. Although EPO has 
demonstrated greater potency than SBP, the effectiveness of SBP, combined with its numerous 
benefits compared to EPO, including low cost, availability, stability and safety make it a much 
greater therapeutic candidate in both its effectiveness and economic use. The work conducted 
here addresses a critical aspect of this thesis which was to identify a cheaper yet comparable 
peroxidase to EPO, in the context of promoting osteoblast functionality. Moreover, when 
compared to the complications and high cost associated with BMP-2, SBP may be considered 
an attractive option. Finally, although being plant-derived, SBP possessed the capacity to 
promote expression of pro-inflammatory and ECM remodelling genes, which are critical for 
successful bone repair. This suggests that SBP can influence human osteoblast function beyond 





The third aim of this study was to assess whether localised delivery of SBP, using 
commercially available scaffold materials could enhance bone repair at a locally targeted site. 
For this study, biphasic granules comprised of HA/β-TCP were pre-treated with SBP and 
dispensed into bilateral femoral condyle defects in adult sheep. Whilst it could be argued that a 
fracture model would provide information of greater value, the simplistic approach for a novel 
agent was to assess its effectiveness in a critical size defect (CSD) model. The results of this 
preliminary study demonstrated that while HA/β-TCP granules are an effective osteoconductive 
material, SBP significantly increased intramembranous bony healing beyond the scaffold alone 
at 4 weeks, as shown by micro-CT analysis. Toluidine Blue staining of bone defects revealed 
no distinct difference in local cell populations between SBP-treated and control groups. Taken 
together, SBP enhanced the biphasic granules’ ability to promote bone formation, with no 
observable toxic effects at the localised region. Since bone regeneration can take up to 12 weeks 
in sheep, long-term studies will be required to assess the continuing effects of these enzymes 
in vivo and confirm their non-toxic effects, as this is a critical determinant for the clinical use 
of novel agents.   
However, the prohibitively expensive nature of the sheep model together with the 
number of sheep needed to provide statistical power made it unfeasible to pursue at this stage, 
thus, we explored validating SBP in a high throughput mouse model. This would allow us to 
explore fracture models in rodents and the use of various scaffold-materials and multiple end 
points with greater efficiency. CSD mouse models are commonly established in the calvaria of 
the skull, specifically the parietal bones (Aalami et al., 2004; Cowan et al., 2004). Whilst the 
long bones, which was the site of the ovine model, differ anatomically to the calvaria and can 
heal more rapidly due to the additional benefit of mechanical loading, the structure of trabecular 
bone in the ends of long bones, is comparable to flat bones including the calvaria (R. B. Martin, 




CSD model successfully in mice. Therefore, the CSD model in the calvaria was utilised as a 
high-throughput model to assess the bone regenerative potential of SBP, instead of a long bone 
defect or fracture model. However, in this study, inhibition of bone formation was observed in 
SBP treated defects (Ch. 5, Fig. 3) with a significant fibrous tissue presence and an absence of 
remodelling indicators, including osteoclasts (Ch. 5, Fig. 4). The mouse CSD model is well-
established in the literature and was successfully reproduced by our laboratory as shown by the 
successful partial healing when using an osteoconductive scaffold alone as the control. It can 
therefore be concluded that the inhibition of bone formation observed in the presence of SBP, 
was not a result of failure to reproduce the CSD model, but likely due to the dose of SBP used. 
The inhibition of bone repair and absence of osteoclast-positive TRAP staining of the SBP 
treated defect sites suggests that the high concentrations tested, were impairing numerous bone 
repair and remodelling processes. For successful bone healing to occur there must be constant 
communication between sufficient population numbers of osteoclasts and osteoblasts (T. J. 
Martin & Sims, 2005). It is therefore plausible based on these studies and the absence of 
osteoclasts at the defect site, the concentrations of SBP utilised in this study significantly 
inhibited osteoclast formation, which resulted in disruption of cellular communication to repair 
the bony defects. However, given that our recent findings indicate that peroxidases possess a 
pro-fibrogenic and angiogenic response both in vitro and in vivo (DeNichilo et al., 2015; 
Panagopoulos et al., 2015), combined with data presented in this thesis, at optimal doses, 
peroxidases can promote tissue repair. Therefore, further studies which involve testing a broad 
range of peroxidase concentrations and determining the underlying mechanism(s) by which 
peroxidases regulate osteoblast and osteoclast function are needed. Future in vivo studies must 
involve careful consideration of dosage to prevent inhibitory responses from occurring.  
Taken together, the significant findings observed in the sheep model presents a proof-




the pro-osteogenic role observed in vitro. The results obtained in the mouse model clearly 
present the issues of optimisation in pre-clinical models and whilst the result may be concerning 
for the future of SBP in the context of bone repair, the evidence presented in the physiologically 
comparable sheep model was positive. Further studies and more robust ex vivo analyses are 
needed to ensure that SBP is an effective agent pre-clinically and optimisation within the high 
throughput rodent model will be beneficial for establishing future models, including fracture 
models. Fracture models are of interest due to the relationship inflammation has on successful 
fracture healing and the known pro-inflammatory role of peroxidases. Thorough studies using 
multiple models and species, including future sheep studies to validate rodent models are 
necessary to fully elucidate the therapeutic potential of peroxidases in bone repair.  
The findings in this thesis not only demonstrate a new functional role for peroxidases 
in promoting osteoblast function, but also provide the foundations for future studies where 
optimisation of these enzymes could be beneficial as novel therapeutic agents to enhance bone 
repair. In addition, the potential link that peroxidases have in pathological ossification provides 
us with the opportunity to explore the use of selective peroxidase inhibitors to manage the 










The limitations of current bone graft substitutes are a major challenge for orthopaedic 
surgeons for managing complex bone defects and fractures. Due to the limitations of gold-
standard autologous grafting and severe adverse effects associated with alternative bone graft 
substitutes, such as BMP-2, there is a need to identify alternative osteoinductive agents. The 
current study suggests that peroxidases, whether plant or mammalian-derived such as SBP and 
EPO, have the capacity to act as osteoinductive agents by their ability to promote osteoblast 
function. Furthermore, this thesis has presented evidence that SBP has the ability to promote 
bone formation in vivo. These preliminary studies identify a potential new range of 
osteoinductive agents for aiding bone repair. However, the work presented in this thesis also 
presents conflicting results for peroxidase enzymes in promoting bone repair, as seen in chapter 
5, which shows significant inhibition of murine calvaria bone repair, when treated with high 
concentrations of SBP. Whilst one could argue the data presented in chapter 4, demonstrating 
the ability of SBP to increase bone repair of an ovine defect model is conducted in an animal 
of greater physiological relevance to humans, it is evident that further studies and robust 
analyses need to be performed to optimise the concentration of SBP to investigate bone healing. 
Well-established mouse models of fracture healing that also offer high throughput analysis in 
drug development exist and are likely more amenable to testing the clinical utility of SBP. 
Rodents are a useful animal model for testing therapies, due to being inexpensive compared to 
large animals and in this context a much more relevant model of bone repair. Once a range of 
optimal doses of SBP has been identified using the CSD model, more complex models of bone 
repair can be explored. This includes the fracture repair model of the long bones, which involves 
a greater complexity of remodelling mechanisms, a significantly greater inflammatory response 




the osteoinductive potential peroxidases have and optimisation of this enzyme could lead to the 
development of a clinically effective agent to improve the rate of bone healing in patients.       
The work described in this thesis identifies a previously unrecognised role for 
peroxidase enzymes on osteoblast functionality, associated with increased expression of 
osteogenic genes, including autocrine intermediate BMP-2. It is well established that autocrine 
BMP-2 production is essential for activating downstream targets in osteoblasts, necessary for 
osteoblast differentiation and bone formation (Phimphilai, Zhao, Boules, Roca, & Franceschi, 
2006). Further findings presented by this thesis indicate that peroxidases are rapidly bound and 
internalised by primary osteoblasts and can promote mineralisation of these cells in vitro. 
Collectively, these findings suggest that one mechanism by which peroxidases increase 
mineralisation is by promoting endogenous BMP-2 production. Future studies investigating the 
role peroxidases have on BMP-2 production and therefore osteoblast function will be vital in 
their development as a therapeutic agent. The use of small molecule BMP inhibitors will be 
vital for investigating the mechanistic link between peroxidases and BMP signalling. A recently 
described BMP inhibitor called K02288, has demonstrated successful inhibition of stimulated 
Smad1/5/8 phosphorylation, without affecting TGF-β signalling (Sanvitale et al., 2013). This 
particular BMP inhibitor has also shown greater potency and selectivity than other small 
molecule BMP inhibitors, including Compound C and LDN-193189 (Vogt, Traynor, & 
Sapkota, 2011). By blocking BMP-2 signalling with the use of an inhibitor we will be able to 
determine if EPO and SBP directly upregulate BMP-2 production or by an independent 
mechanism.  
An alternative mechanism by which peroxidases promote osteoblast activity is through 
depletion of ROS. ROS, including H2O2 are generated during normal cellular metabolism and 
at high levels can push cells into a state of oxidative stress, which is detrimental to cellular 




differentiation of pre-osteoblastic cells such as MC3T3-E1, primary rabbit osteoblasts and bone 
marrow stromal cells (Mody, Parhami, Sarafian, & Demer, 2001). The precise mechanism by 
which oxidative stress-induced inhibition of osteoblast differentiation occurs is still unclear. 
However, there is sufficient evidence that activation of both ERK and NF-KB are essential for 
the oxidative-stress induced inhibition of both alkaline phosphatase activity and collagen type 
I expression (Bai et al., 2004). It is well-established that peroxidases utilise H2O2 as a substrate 
to generate ROS. Based on this knowledge and our data, which demonstrates rapid binding and 
internalisation of peroxidases by cultured osteoblasts (DeNichilo et al., 2016) raises the distinct 
possibility that peroxidases can regulate intracellular H2O2. Therefore, we hypothesise that a 
potential mechanism by which peroxidases regulate osteoblast function in the context of 
osteogenesis is by depleting intracellular H2O2 levels. To assess this potential mechanism, in 
vitro studies will be conducted to determine the intracellular ROS levels of osteoblasts after 
peroxidase treatment. This will be assessed by measuring oxidative stress of osteoblastic cell 
cultures, using 2,7 dichlorofluorescein diacetate (DCF), a cell permeable dye which becomes 
fluorescent once reacted with intracellular ROS, such as H2O2 (Mody et al., 2001). We 
anticipate that these studies will collectively shed light on the mechanism(s) by which 
peroxidases regulate osteoblast function. These findings will be necessary to provide further 
understanding of how peroxidases function in vivo, which will enable us to further optimise this 
enzyme for pre-clinical and potentially in the future, clinical use. 
Whilst there are several options available to manage and treat pathological ossification, 
including heterotopic ossification (HO), such as nonsteroidal anti-inflammatory medications 
(NSAIDs), bisphosphonates, radiation and physical therapy, there is a lack of clinical 
improvement for non-surgical interventions (Ranganathan et al., 2015). Operative intervention 
is currently the most successful treatment option, however severe complications can occur and 




the mechanistic processes involved in the progression of HO are not clearly defined, which has 
made targeted treatment of HO difficult, evidence suggests a mechanistic link between the local 
inflammatory response and HO development (Convente, Wang, Pignolo, Kaplan, & Shore, 
2015). Specifically, enhanced recruitment of wound healing fibroblasts and a shift from normal 
soft tissue repair towards ectopic bone formation. Furthermore, it is hypothesised that treating 
HO at the inflammatory stage, prior to the formation of osseous tissue would be the ideal 
treatment strategy. However, the only current form of treatment in this context is the use of 
broad immunosuppressive drugs and whilst these drugs have shown success in inhibiting HO 
formation, therapies which target specific immune cells, including macrophages and 
neutrophils could be of greater benefit (Kraft et al., 2016). In addition to HO, the potential link 
between eosinophil infiltration and ectopic bone formation in chronic rhinosinusitis patients 
suggests a potential treatment target for this disease and others where increased eosinophilia is 
observed. The work presented in this thesis suggests that peroxidase enzymes, MPO and EPO 
are involved in multiple cellular processes critical to bone formation, which suggests a potential 
link for these enzymes in pathological ossification. Furthermore, it identifies a potential new 
avenue of targeted therapy for pathological ossification, where inflammation plays a critical 
role in the progression of these diseases. Small molecule peroxidase inhibitors have been 
developed over the years which have demonstrated their effectiveness with minimal detrimental 
effects (Kubin, 2011; Winterbourn, Kettle, & Hampton, 2016). These inhibitors have been 
designed specifically for inflammatory diseases such as chronic asthma and chronic sinusitis. 
Having now established a potential link for mammalian-derived peroxidases in pathological 
ossification, MPO and EPO inhibitors should be further investigated for their targeted anti-
inflammatory therapy and subsequent prevention of ectopic bone formation. This would require 
the use of small animal models which mimic acquired HO, such as BMP-4-overexpressing mice 




peroxidases have in inflammation but also the effect inflammation has on the progression of 
pathological ossification. Furthermore, by conducting studies utilising peroxidase inhibitors, 
we may increase our understanding of the mechanisms involved between peroxidases and 
osteogenesis, which subsequently may provide further knowledge of the role these enzymes 
have as therapeutic agents for bone repair. 
Collectively, these future directions will not only provide valuable pre-clinical 
information that will help determine the therapeutic capacity of peroxidases in enhancing bone 
repair, compared to current osteoinductive agents, but also allow us to develop therapies which 
target MPO and EPO selectively against pathological ossification, thereby potentially inhibiting 

















The findings presented in this thesis provide novel insights into the role of peroxidase 
enzymes in bone repair. MPO, EPO and SBP were proven to exhibit potent effects in inducing 
formation of the extracellular matrix, which is critical for ensuring successful bony healing. 
EPO and SBP were also recognised to be effective promoters of osteoblast function by 
regulating osteogenic gene expression and matrix mineralisation. The physiological relevance 
of EPO in promoting osteoblast function and its release from eosinophils at sites of 
inflammation suggests a potential mechanistic link for EPO in pathological bone formation at 
sites of tissue eosinophilia. Importantly, SBP has demonstrated the ability to enhance bone 
repair at a locally targeted site. The discovery that plant-derived SBP, like EPO, can promote 
osteoblast function, whilst also effectively enhance bone repair in vivo, gives rise to the idea of 
utilising novel non-mammalian-derived, cheaper agents which are easier to manufacture for 
promoting tissue regeneration. 
In conclusion, data presented in this thesis demonstrates that peroxidase enzymes 
possess the capacity to regulate multiple cellular processes by osteoblasts, including collagen I 
biosynthesis, matrix mineralisation and regulate numerous pro-osteogenic genes. This thesis 
has also demonstrated the potential role SBP could have in a clinical setting by its ability to 
significantly enhance localised bone formation in a physiologically relevant animal model. 
Collectively, the findings of this thesis provide new evidence for peroxidase enzymes as novel 
osteoinductive agents likely to be used locally, in combination with bone graft substitutes to 
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